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TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED 
RESISTANCE AND CHARACTERIZATION OF IMMUNE 
RELATED TOXICITIES  
Ashvin R. Jaiswal, M.S. 
Advisory Professor: Michael A. Curran, Ph.D 
Tumor immunotherapy has shown very promising clinical benefit across an 
array of cancers; however, two major challenges remain unresolved in the field.  
First, many patients do not respond to therapy at all or relapse after a period of 
remission. Second, there are often dose-limiting immune related adverse effects 
associated with immunomodulation.  
In order to understand the mechanisms employed by tumors to evade 
immunotherapeutic responses, we established a murine model of melanoma 
designed to elucidate the molecular mechanisms underlying immunotherapy 
resistance. Through multiple in vivo passages, we selected a B16 melanoma tumor 
line that evolved complete resistance to combination blockade of CTLA-4, PD-1, 
and PD-L1, which cures ~80% of mice bearing the parental tumor. Using gene 
expression analysis, and immunogenomics, we determined the adaptations 
engaged by this melanoma to become completely resistant to triple combination T 
cell checkpoint blockade. Acquisition of immunotherapy resistance by these 
melanomas was driven by the coordinated upregulation of the glycolytic, 
oxidoreductase, and mitochondrial oxidative phosphorylation pathways to create a 
metabolically hostile microenvironment wherein T cell functions are suppressed. 
Together these data indicate that by adapting a hyper-metabolic phenotype, 
VIII 
 
 
 
melanoma tumors can achieve resistance to T cell checkpoint blockade allowing 
them to escape host immune control. 
Increasing the potency of antitumor immunity with immunotherapy disrupts 
the tightly controlled state of immunologic homeostasis in the body which can lead 
to reactivation of peripherally-tolerized T cell responses with the potential to 
mediate uninvited toxicities. Agonist antibodies targeting the T cell co-stimulatory 
receptor 4-1BB (CD137) are among the most effective immunotherapeutic agents 
across pre-clinical cancer models.  Clinical development of these agents, however, 
has been hampered by dose-limiting liver toxicity.  Lack of knowledge of the 
mechanisms underlying this toxicity has limited the potential to separate 4-1BB 
agonist driven tumor immunity from hepatotoxicity. The capacity of 4-1BB agonist 
antibodies to induce liver toxicity was investigated in wild type and genetically-
modified immunocompetent mice. We find that activation of 4-1BB on liver myeloid 
cells is essential to initiate hepatitis.  Once activated, these cells produce 
interleukin-27 that is required for liver toxicity.  CD8 T cells infiltrate the liver in 
response to this myeloid activation and mediate tissue damage.  Co-administration 
of CTLA-4 and/or CCR2 blockade may minimize hepatitis, but yield equal or 
greater antitumor immunity.  
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1.1: Introduction 
 After the breakthrough discovery of the first immunotherapeutic agent 
(CTLA-4) that offered a long term survival benefit in metastatic melanoma, the 
focus of cancer medicine shifted from targeting the tumor itself to harnessing the 
immune system to eliminate cancer cells.   The concept of using one’s own immune 
system to treat cancer was pioneered by Dr. William Coley, who inoculated 
sarcoma patients with Streptococci to stimulate anti-tumor immune responses 
against the infected cancer cells (1). The immunosurveillance theory coined by Dr. 
F. M. Burnet states that immune cells, in addition to defending the host against 
invasion by microorganisms, can also mediate responses against abnormal cells 
such as malignant cancer cells, based on their distinct antigenic qualities 
compared to healthy cells (2). In recent years, the concept of a cancer 
immunoediting theory, introduced by Dr. Schreiber, describes that immune cells 
not only eliminate tumor cells but also shape their immunogenicity and clonal 
diversity through immuno-selection (3-5). Anti-tumor immunity affects tumor 
growth and progression in three sequential phases: elimination, equilibrium and 
escape (3E) (3-5). First, immune cells try hard to eliminate cancer cells through 
immune mediated cell death. This is followed by the second phase where tumor 
cells establish an equilibrium with the immune system by hiding from immune 
attacks and creating an immunosuppressive tumor microenvironment (TME) (3-5). 
In the last stage, a highly immunosuppressive niche assists tumor cells to escape 
anti-tumor immune attack (3-5). T cells make major contributions in the 
immunosurveillance and immunoediting processes. Tumors evade immune attack 
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largely by escaping T cell mediated cell death. Hence, improving T cell responses 
has been the recent focus of the tumor immunology field.   
T cell activation involves the binding of T cell receptor (TCR) to antigen, 
presented in the context of major histocompatibility complex (MHC) I or II, on 
antigen presenting cells (APCs). TCR activation also requires a second co-
stimulatory signal mediated by the binding of CD28 on the T cell surface to B7-1 
(CD80) or B7-2 (CD86) present on APCs(6). As a negative feedback loop, 
activated T cells increase CTLA-4 expression on their cell surface. Seminal work 
from Dr. James P. Allison and colleagues showed that CTLA-4, which also belongs 
to the B7 family of receptors, competitively inhibits the binding of B7 molecules to 
CD28 and inhibits T cell activation and proliferation (7). CTLA-4 blockade with anti-
CTLA-4 antibodies blocks CTLA-4 binding to B7-1/-2, which are then freely 
available to bind to costimulatory CD28 molecules and provide a second 
stimulatory signal for T cell-mediated immune responses (6). CTLA-4 was the first 
immune checkpoint blockade therapy approved by Food and Drug Administration 
(FDA) for unresectable stage III and IV metastatic melanoma. In about 20% of 
melanoma patients, CTLA-4 therapy provides long term survival benefit (8-10).  
Another extensively studied immune checkpoint receptor that regulates 
activation and effector function of CD8 T cells is the programmed death 1 (PD-1) 
receptor.  PD-1 on T cells, after engagement by its ligands (PD-L1 and PD-L2) on 
tumor cells or hematopoietic cells, becomes phosphorylated (11). The cytoplasmic 
domains of PD-1, an immune-receptor tyrosine-based inhibitory motif (ITIM) and 
an immunoreceptor tyrosine-based switch motif (ITSM), when phosphorylated, 
recruit protein tyrosine phosphatases (SHP1 and SHP2) (12) which ultimately 
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dephosphorylate T cell signaling molecules, Lck and ZAP70 (11,12).  Lck and 
ZAP70 are part of the TCR-CD28 downstream signaling cascade and 
dephosphorylation leads to inhibition of T cell activation and function (11).   
Blocking the PD-1/ PD-L1 axis has been shown to increase antitumor immune 
response in various preclinical tumor models. PD-1 blocking antibodies have 
achieved substantial success in clinic offering long term survival advantages in an 
array of tumor types leading to their FDA approval to treat melanoma (8,13), non-
small cell lung cancer (NSCLC) (14-16), renal cell carcinoma (RCC) (17), Hodgkin 
lymphoma (18,19), urothelial carcinoma (20), Merkel cell carcinoma, and head and 
neck SCC (21,22). Similarly, PD-L1 blocking antibodies have shown promising 
clinical results and are gaining approval for an expanding array of indications (22). 
There are other T cell checkpoint receptors such as TIM3, LAG3, and VISTA, 
which have shown anti-tumor immune response in preclinical studies and are 
under  clinical investigation  (23).  
TCR activation through co-signaling is a tightly regulated process. Along 
with co-inhibitory checkpoint receptors, T cells also possess co-stimulatory 
receptors on their surface which positively regulate T cell responses (24). CD28, a 
member of the immunoglobulin superfamily (IgSF), is the most well characterized 
co-stimulatory receptor , which up-regulates cell-survival genes and fosters 
expansion of antigen-specific T cells into effector and memory phenotypes (24). 
CD28 signaling enhances the production of interleukin-2 (IL-2), IFN-γ, TNFα and 
other cytokines. Most of the other co-stimulatory molecules on T cells belong to 
the tumor necrosis factor receptor superfamily (TNFRSF) such as 4-1BB 
(CD137/TNFRSF9), GITR (CD357/ TNFRSF18) and OX40 (CD134/ TNFRSF4). 
5 
 
 
 
These molecules have structural similarities to CD28 and drive co-stimulatory 
functions (24). Agonist antibodies targeting 4-1BB (CD137/TNFRSF9) and OX40 
have shown promising preclinical results and are under evaluation in ongoing 
clinical trials (25,26).   
Immunomodulatory receptors (co-inhibitory and co-stimulatory) maintain 
immune homeostasis in the body (27). Checkpoint receptors on T cells are 
negative feedback mechanisms which the body uses to shut down the immune 
response after an infection/tumor is eliminated. Anti-checkpoint receptor 
antibodies or agonist antibodies targeting co-stimulatory molecules disturb 
immune homeostasis and can lead to immune-related adverse events (IRAEs), in 
dermatologic, gastrointestinal, hepatic, endocrine, and other tissues (28). Steroids 
are used in the clinic to manage immune related adverse events (IRAEs), but due 
to their immunosuppressive nature, steroids may compromise the anti-tumor 
immune response (27). Detailed understanding of immune resistance and the 
mechanisms undrlying IRAEs will help facilitate design of new therapeutic 
strategies to overcome resistance to immunotherapy without the associated 
immune toxicities. This chapter reviews the current and ongoing work focused on 
understanding mechanisms driving resistance to immunotherapy and 
pathophysiology of immune related toxicities associated with immunomodulatory 
antibodies.   
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Figure 1.1 
 
Figure 1.1: Emerging mechanisms of resistance to checkpoint blockade 
immunotherapy. β2M=β-2-microglobulin, CANX=calnexin. CTLA-4= cytotoxic T-
lymphocyte-associated protein-4, ER=endoplasmic reticulum, FasL=ligand for 
FAS receptor, IFN-γ=interferon gamma, IFNGR=IFN γ receptor, JAK=Janus 
kinase, LAG3=Lymphocyte-activation gene-3, PD-1= program cell death protein-
1, PIAS4=protein inhibitor of activated STAT4, SOCS1=suppressor of cytokine 
signalling-1, STAT=signal transducer and activator of transcription, 
TAP=transporter associated with antigen processing, TCR=T-cell receptor, 
TIGIT=T cell immunoreceptor with Ig and ITIM domains, and TIM-3= T-cell 
immunoglobulin and mucin-domain containing-3. 
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1.2: Mechanisms of resistance to checkpoint immunotherapy 
  
There are large ongoing efforts to understand the mechanisms of resistance 
to immunotherapy. A number of escape pathways engaged by tumor cells in order 
to evade immunotherapeutic pressure have been described such as altering 
antigen presentation and recognition, creating an immunosuppressive 
microenvironment, upregulating alternative checkpoint receptors of effector CD8 T 
cells, and other pro-tumor mechanisms (Figure 1.1).   
1.2.1: Alteration in antigen presentation and defects in T cell recognition  
 The success of the adaptive immune response relies on the recognition of 
antigen by T cell receptors (TCR).  To prime the T cell mediated immune response, 
T cells have to recognize the antigen presented as a peptide on major 
histocompatibility complex (MHC-I or II) molecules through TCR.  The intensity of 
the T cell mediated immune response depends on the multi-step process and 
quality of interaction between TCR and peptide MHC complex. Tumor cells hijack 
these processes at various stages to evade the immune response by 
downregulating or mutating antigen presentation machineries, and/or by 
eliminating CD8 T cells from the TME. In addition to this, tumor intrinsic genetic 
changes further enable tumor cells to become resistant to T cell mediated killing.    
a) Antigen presentation 
The protein antigens in cancer cells undergo proteasomal degradation to 
produce peptides ranging from 8 to 11 amino acids in length (29). The resulting 
peptides are transported to the endoplasmic reticulum (ER) where they are loaded 
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onto MHC-I molecules (29). The peptide MHC-I complex then shuttles to the cell 
surface where they are recognized by TCR on CD8 T cells (29). CD8 T cells scan 
peptide MHC complexes on normal, infected and cancer cells. CD8 T cells 
eliminate infected cells that present foreign antigens and cancer cells that present 
neo-antigens (29). Normal cells remain safe from CD8 mediated killing since they 
present self-antigens (29). 
MHC-I in humans is also known as human leukocyte antigen (HLA) class I. 
A heavy-chain and beta-2-microglobulin (β2M) are crucial protein domains for the 
successful assembly of HLA class I complexes (30). Cancer cells are shown to 
alter β2M to escape immune responses either by mutation, deletion or loss of 
heterozygosity (LOH). Giannakis et al. showed that along with β2M, other genes 
in  antigen presentation machinery (APM) were also altered in colorectal cancer 
(CRC) patients (31).  They have identified 96 different mutations in 11% of patients 
which correlated with immune infiltration (31).  They have also observed mutations 
in other APM pathways like protein folding process (CANX and HSPA5), the 
endoplasmic reticulum (ER) and peptide loading complexes (TAP, TAPBP, CALR 
and PDIA3) which also showed correlation with immune infiltration (31). Sade-
Feldman et al. showed metastatic melanoma patients treated with checkpoint 
blockade immunotherapy (anti-CTLA-4, anti-PD1) acquired resistance through the 
loss of β2M either by point mutations, deletions or loss of heterozygosity (LOH).  
In a separate validation cohort, β2M LOH events were significantly enriched in 
about 29% of patients who did not responded to anti CTLA-4 therapy. These 
patients also showed a strong association between β2M LOH and poor overall 
survival. Similarly, in the second validation cohort of patients who did not respond 
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to anti-PD-1 therapy, β2M LOH was significantly associated with worse overall 
survival. Jesse Zaretsky and Antoni Ribas, in a recent study showed that acquired 
resistance to anti PD-1 therapy was associated with deletion in the β2M 
component in a late-relapse patient with metastatic melanoma. Together, all the 
studies suggest that in order to elicit a successful response to checkpoint blockade 
immunotherapy, an efficient tumor antigen presentation pathway is needed. Tumor 
cells have the ability to alter these pathways and evade therapeutic responses.  
b) Mutation load and neoantigen burden 
Effector T cells distinguish cancer cells from healthy tissue based on the 
antigen presented on their surface. Healthy cells present self-antigens for which 
potentially reactive T cells have been tolerated. (32).  On the other hand, cancer 
cells acquire tumor-specific mutations which results in the formation of novel 
protein sequences and potential MHC loading of neoantigen peptides (32). Effector 
T cells recognize these neoantigen peptide-MHC complexes and generate tumor 
specific immunity. The strength of tumor specific antitumor T cell immunity 
depends on the quantity and quality of mutation loads and resulting neoantigen 
peptides (32).   
By using whole-exome sequencing, Rizvi and colleagues showed that a 
high nonsynonymous mutation burden is associated with improved objective 
clinical responses, durable clinical benefit, and progression-free survival in non–
small cell lung cancers (NSCLC) treated with anti-PD-1 antibodies (33). Several 
other studies have highlighted the importance of neoantigens along with mutational 
landscapes in recognition of cancer cells by the immune system and mediating 
immunotherapy response (4,32,34-36). McGranahan et al. also highlight the role 
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of heterogeneity of intratumoral neoantigens on anti-tumor immune response 
following anti-CTLA-4 and anti-PD-1 therapy in advanced lung cancer and 
melanoma. Moreover, many tumors are non-immunogenic in nature since they 
have a low neo-antigenic mutational load resulting in natural (primary) resistance 
to immunotherapy (37). These studies together suggest that tumor cells acquire 
resistance to immune mediated attack by decreasing expression of mutated genes 
and resulting neo-antigen peptides 
 The mutational landscape/neoantigen burden could be used to design 
therapeutic strategies such as neoantigen peptide vaccination to reverse 
resistance. Using a peptide immunization approach, Uger Sahin and colleagues 
showed the beneficial effects of immunization with neoantigen peptide vaccine in 
combination with checkpoint immunotherapy in a preclinical B16 melanoma model. 
The current research focus in the field is predicting immunotherapy responses 
using mutational landscape/neoantigen burden, applying the knowledge to reverse 
resistance using therapeutic approaches such as peptide or RNA vaccination, and 
inducing changes in the mutational landscape of non-immunogenic tumors using 
chemotherapy and/or radiotherapy.  
c) TCR repertoire  
The success of checkpoint blockade immunotherapies depends on the 
clonal diversity and number of tumor specific cytotoxic T cells within the tumor 
microenvironment. There is evidence which suggests that high mutational 
landscape and neoantigen burden cannot ensure the presence of cytotoxic T cells 
in the tumor microenvironment (38). Moreover, patients who relapsed on anti-
CTLA-4 and anti-PD-1 therapy responded to adoptive T cell transfer (ACT) (39). 
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Together, these findings suggest that an abundance of T cells in tumor 
microenvironment is equally important in mediating antitumor immune responses 
(38,39).  
Several tumor intrinsic oncogenic pathways have been identified which are 
involved in exclusion and elimination of tumor specific CD8 T cells from the tumor 
microenvironment. BRAF inhibition increases CD8 T cell infiltration in melanoma, 
which otherwise was inhibited by persistent tumor specific activation of mitogen-
activated protein kinase (MAPK). Tumor intrinsic activation of MAPK triggers 
release of interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) which 
inhibits CD8 T cells trafficking into tumors (40).  Oncogenic loss of PTEN, a tumor 
suppressor gene, activates PI3 kinase and increases the expression of 
immunosuppressive cytokines on tumor cells which, ultimately, inhibits T cell–
mediated tumor killing and decreases T-cell trafficking into tumors (41). In a 
preclinical mouse melanoma model and in human metastatic melanoma samples, 
constitutive activation of the WNT/β-catenin signaling pathway resulted into tumor 
T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody 
therapy (42). In addition, mouse tumor models also show that WNT/β-catenin 
activation leads to a decrease in CD103+ DCs in the tumor microenvironment 
which negatively impacts cytotoxic CD8 T cell abundance and clonal diversity (42).  
These studies suggest that tumors use intrinsic oncogenic pathways to reduce 
infiltration and clonal diversity of antigen-specific CD8 T cells in TME.   
d) Tumor cell intrinsic insensitivity to T cell recognition  
Checkpoint blockade immunotherapy increases cytolytic cytokines like 
interferon-γ (IFNγ), granzymes, perforin, and tissue necrosis factor α (TNF-α) on 
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effector CD8 T cells (43,44).  Effector CD8 cells deliver these cytolytic cytokine 
loads to target tumor cells and induce T cell mediated cell death (44).  T cell derived 
IFNγ restrains cancer cell growth directly by inducing anti-proliferative and pro-
apoptotic effects, as well as indirectly by enhancing tumor antigen presentation 
through MHC-I upregulation, which ultimately increases recruitment of antitumor 
immunity. However, persistent exposure to IFNγ can drive STAT1-related 
epigenomic and transcriptomic changes in cancer cells and augment alteration in 
interferon-stimulated genes (45). Gao and colleagues have shown that loss in IFNγ 
pathways drives the resistance mechanisms to anti-CTLA-4 therapy. Melanoma 
patients who failed to respond to anti-CTLA-4 therapy accumulated copy number 
alterations and genomic loss of IFN-γ pathway genes such as IFNGR1, IRF1, 
JAK2, and IFNGR2 (46). In preclinical studies, anti-CTLA4 therapy could not 
deliver therapeutic benefit to B16 murine melanoma tumors lacking IFNGR1 (46), 
while the wild type cell line is known to be anti-CTLA-4 sensitive (47).   Sucker et 
al. showed that human melanoma patients who have a mutation in JAK1/2 are 
resistant to IFN-γ induced cell death (48). The loss of IFN-γ pathway genes, such 
as JAK1 and JAK2, are shown to be also associated with resistance to anti-PD-1 
therapy (49). Tumor cell escape of interferon mediated cell death by down 
regulating interferon pathways additionally results in downregulation of IFN-
induced PD-L1 expression on tumor cells (45). PD-L1 negative tumors could also 
fail to respond to anti-PD-1 and anti-PD-L1 therapy. Therefore, genetic defects in 
the IFN-γ pathway could represent one of the mechanisms of acquired resistance 
to checkpoint therapies (46,49).  
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1.2.2: Tumor microenvironment (TME)  
A tumor is not just a mass of cancerous cells, but consists of a complex of 
cancerous and noncancerous cellular structures along with their extracellular 
milieu, which together create the tumor microenvironment (TME). Tumor cells 
influence the microenvironment by releasing extracellular signals, depleting 
nutrients, creating a state of hypoxia, promoting angiogenesis, and recruiting tumor 
promoting cells like cancer associated fibroblasts (CAF) or suppressive myeloid 
stroma (myeloid derived suppressor cells (MDSC)). The tumor microenvironment 
creates unfavorable conditions for effector T cells to function, which could also 
potentially mediate acquired resistance to checkpoint immunotherapy (Figure 1.1).  
a) Hypoxia  
Tumor cells create a state of hypoxia by depleting oxygen from the tumor 
microenvironment, often by increasing mitochondrial oxidative phosphorylation 
which induces expression of the hypoxia-inducible factors (HIFs) transcription 
factor family. HIF-1α and HIF-2α, in turn, induce hypoxia responsive genes in 
tumor cells and help them adapt to the self-created hypoxic condition. The role of 
hypoxia is well characterized in tumorigenesis and angiogenesis. Emerging 
research also suggests its role in mediating resistance to immunotherapeutic drugs 
(50). In hypoxic conditions, tumor cells also switch to glycolytic metabolism, 
releasing lactic acid and creating an acidic tumor microenvironment. The low 
oxygen and acidic pH decrease T cell activation, proliferation and cytotoxicity (50-
54). Hypoxic tumors secrete miR-210, which ultimately inhibits cytotoxic T cell 
mediated killing of target cells. Additionally, T cells induce HIF-1α in response to 
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hypoxia, which induces cell intrinsic immunosuppressive changes in T cells 
(50,55).  
Hypoxia induces the production of immunosuppressive cytokines like 
interleukin-10 (IL-10), interleukin-6 (IL-6), transforming growth factor-β (TGF- β) 
and Arginase by myeloid derived suppressor cells (MDSC), Tumor associated 
macrophages (TAM), cancer associated fibroblasts (CAF), and stromal cells. 
Through its effect on multiple cell types in the TME, hypoxia reduces the 
therapeutic benefits of immunotherapy. Thus, targeting hypoxia in combination 
with immunotherapy has shown synergistic effects in preclinical studies (56,57).  
Prostate tumors are considered non-immunogenic (immunologically cold) tumors 
and they fail to respond to checkpoint immunotherapies. We have recently shown 
that the hypoxia-activated prodrug TH-302 not only ablates hypoxia but also 
sensitizes TRAMP-C2 prostate tumors to checkpoint immunotherapy (56). A 
combination of TH-302 and T cell checkpoint blockade therapy showed synergistic 
survival benefit in highly aggressive prostate adenocarcinoma (56). Scharping et 
al. also showed beneficial effects of ablating hypoxia in a B16 melanoma model 
when combined with anti PD-1 therapy (57).  
b) Metabolic insufficiency  
Tumor cells create a hostile microenvironment for immune cells to function. 
Tumor cells deplete the microenvironment of glucose, oxygen, glutamine, and 
tryptophan while enriching it with lactate. The combination of low glucose and high 
lactate creates unfavorable conditions for cytotoxic CD8 T cells where they lose 
their metabolic fitness and associated effector functions. However, regulatory T 
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cells thrive under low glucose and high lactate conditions and become more 
immune suppressive (58).  
 Under conditions of chronic antigen stimulation such as cancer and chronic 
virus infection, CD8 T cells have demonstrated exhaustion even in the absence of 
immune checkpoint molecules, which raises the argument on the role of other T 
cell intrinsic pathways in executing CD8 effector functions (59,60). After antigen 
encounter T cells differentiate into effector phenotypes where they proliferate, 
activate, and carry out effector function through producing cytokines and delivering 
them to target cells. T cell activation, proliferation and execution of cytotoxic 
effector functions are energy demanding processes requiring metabolic fitness. T 
cells switch to glycolytic metabolism to meet these metabolic demands (61-63). 
After resolving infections or eliminating tumors, these cells go back to 
mitochondrial oxidative phosphorylation and fatty acid oxidation, which also play 
important roles in generating T cell memory (64,65). However, recent work from 
Delgoffe and colleagues also emphasizes the importance of mitochondrial mass 
in regulating effector CD8 T cell function (66, 67). Tumors create a chronic 
metabolic deficiency in the microenvironment in which infiltrating CD8 T cells lose 
PPAR-gamma coactivator 1α (PGC-1α), which controls mitochondrial biogenesis 
(66). The persistent loss of mitochondrial function and mass causes T cells to 
adapt an overall phenotype of metabolic insufficiency resulting in loss of effector 
functions. Wherry and colleagues also showed the importance of PGC-1α driven 
metabolism, especially glycolysis and mitochondrial metabolism, in T cell effector 
functions in a chronic virus infection model (LCMV)(67).   
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 There is a metabolic tug-of-war between tumor cells and the immune 
compartment where tumor cells out-compete immune cells for available nutrients, 
causing starved CD8 T cells to lose effector function (68). As a compensatory 
mechanism in a glucose low environment, effector T cells induce AMPK activation 
which reduces energy expenditure by suppressing mammalian target of rapamycin 
complex 1 (mTORC1) (69). AMPK also promotes glutaminolysis as an alternative 
source of ATP production through the TCA cycle and mitochondrial oxidative 
phosphorylation (69). Interestingly, in tumor cells, intergenic AMPK activity inhibits 
cellular metabolic pathways that support tumor development, and loss of AMPK 
activity promotes tumor growth (70). Drs.Ping-Chih Ho and Susan Kaech showed 
that in a glucose-poor microenvironment, reprogramming of glycolytic metabolite 
phosphoenolpyruvate (PEP) could improve T cell effector functions (62). In T cells, 
PEP suppresses sarco/ER Ca2+-ATPase (SERCA), which leads to antigen-
specific-TCR-mediated activation of Ca2+- NFAT signaling, ultimately increasing 
T cell effector functions (62). Kristen Pollizzi and Jonathan Powell showed that 
knocking out T cell-specific Tsc2 increases their glycolytic capacity, making them 
highly cytotoxic and short lived effector T cells. This cytotoxic short lived effector T 
cell phenotype, however, comes at the expense of losing memory potential, since 
Tsc2 knockout T cells lose mitochondrial oxidative phosphorylation (71,72).  
Increasing T cell-specific PEP and inhibiting Tsc2 could be potential therapeutic 
targets to break T cell metabolic insufficiency in the hostile tumor 
microenvironment (62,72,73).  
 In contrast to effector T cells, immune suppressive regulatory T cells not 
only manage to survive in the unfavorable tumor microenvironment, but also 
17 
 
 
 
harness their immune suppressive functions. Alessia Angelin and Ulf Beier have 
shown that in the low glucose and high lactate tumor microenvironment, FoxP3 
alters the metabolism of regulatory T cells, which helps them to adapt to 
metabolically challenging conditions to maintain  immunosuppressive function and 
impair tumor immunity (58). Ongoing work of Watson et al. showed that regulatory 
T cells take up lactate through monocarboxylate transporter 1 (MCT1) and utilize 
it for ATP production which gives them a survival advantage in an LDH high tumor 
microenvironment (74).  
c) Tumor-cell-extrinsic immunosuppressive factors  
 Tumors create an immunosuppressive milieu to escape immunotherapeutic 
pressure by recruiting pro-tumor cells like myeloid-derived suppressor cells 
(MDSC), Treg, and cancer associated fibroblasts (CAF), polarizing macrophage to 
an immunosuppressive M2 phenotype and secreting immunosuppressive 
cytokines and enzymes like arginase, VEGF, indoleamine-2,3-dioxygenase (IDO) 
and IL-8.  
 Tumor cells and MDSCs produce indoleamine-2,3-dioxygenase (IDO), an 
enzyme involved in tryptophan catabolism, generating the immunosuppressive 
metabolite, Kynurenine (75). Further depletion of tryptophan, which is an essential 
amino acid, inhibits T cell expansion and function. This indicates that tumors 
escape immunotherapeutic pressure possibly by inducing IDO (76). In a preclinical 
B16 melanoma model, combining IDO inhibitors with anti-CTLA-4 or anti-PD-L1 
therapy showed synergistic survival benefits (76-78).  Similarly, catabolism of 
arginine, which is mediated by the enzyme Arginase, is also an 
immunosuppressive mechanism (79). Arginase is expressed by tumor cells, 
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MDSCs, tumor associated macrophages (TAM), stromal cells, and fibroblasts 
(78,79).   Arginase expression in the TME suppresses T cell proliferation and 
activation (78). It also repolarizes macrophages to the suppressive M2 phenotype 
(78). This suggests that the expression of tryptophan- and arginine-depleting 
enzymes creates an immunosuppressive milieu in the TME and contributes to 
resistance to immunotherapy (76,78). 
1.2.3: Enteric microbiome 
The intestinal microbiota maintains symbiosis with the host immune system, 
and the inner lining of gut plays an important role as a barrier between them. Any 
dysbiosis caused by repeated antibiotic medication could enhance the frequency 
of some cancers, suggesting a relationship between the microbiome and 
carcinogenesis (80). This gut microbiome is also known to influence immune 
surveillance(81) and pathophysiology of immune-related diseases like obesity 
(82),  diabetes (83), inflammatory bowel disease (84),  experimental autoimmune 
encephalomyelitis (85), multiple sclerosis  (85,86), arthritis (86), and psoriasis (86). 
Gut microbiota not only influence the development and progression of 
gastrointestinal (GI) tract cancers like colorectal cancer (87,88) but also influence 
non-GI cancers like  breast cancers (89,90).   Once barriers are breached, gut 
microbes can further influence tumor immune responses by eliciting 
proinflammatory or immunosuppressive tumor milieu.  
Iida et al. showed that tumor bearing mice that lacked microbiota do not 
respond to drugs that modulate the innate immune system (CpG - cytosine, 
guanosine, phosphodiester link oligonucleotides) and chemotherapeutic agents 
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(e.g. oxaliplatin, a platinum compound).   Viaud et al. found that cyclophosphamide 
treatment induces the translocation of certain species of Gram-positive bacteria 
into secondary lymphoid organs and promotes an antitumor adaptive immune 
response. More recent evidence suggests that the gut microbiome plays a role in 
influencing response to checkpoint blockade antibodies. Sivan et al. and Vétizou 
et al. have shown that resistance to anti-CTLA-4 and anti-PD-L1 therapy was 
mediated by stool microbiota.  Vétizou et al. show that mice treated with antibiotics 
or housed in specific pathogen-free conditions failed to respond to anti–CTLA-4 
therapy.  When antibiotic-treated or germ-free–housed mice were given 
Bacteroides fragilis, resistance to anti-CTLA-4 therapy could be reversed. Sivan et 
al. illustrated that fecal transfer of Bifidobacterium improved survival in response 
to anti–PD-L1 antibody by augmenting dendritic cell functions and ultimately 
enhancing CD8+ T cell function in the TME. In more recent studies, 
Gopalakrishnan et al. and Matson et al. showed that melanoma patients could be 
distinguished as responders or non-responders to anti-PD-1 therapy based on the 
composition of their gut microbiome (91-93). Patients who responded to anti-PD-1 
therapy had greater abundance of “good” bacteria in the gut while non-responder 
patients showed an imbalance in the composition of gut flora, which correlated with 
impaired immune function (91-93). Gopalakrishnan et al. analyzed the oral and gut 
microbiome of 112 melanoma patients who were undergoing anti-PD-1 therapy 
and observed that anti-PD-1 responders had significantly different diversity and 
composition of the gut microbiota compared to non-responders. They also 
examined fecal microbiome from 43 patients and found that abundance of bacteria 
of the Ruminococcaceae family was higher in responding patients. When 
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BRAFV600E/PTEN–/– (BP-1) melanoma tumor bearing germ free mice were 
implanted with fecal microbiome from anti-PD-1 responding patients, mice showed 
improved systemic and antitumor immunity. Matson et al. also showed significant 
differences in the composition of fecal microbiota of 16 patients who responded to 
anti-PD-1 or anti-CTLA-4 therapy compared to 26 non-responders. The bacterial 
species more abundantly found in the responders included Bifidobacterium 
longum, Collinsella aerofaciens, and Enterococcus faecium. When fecal 
microbiome from patients who responded to immunotherapy were transferred to 
B16 melanoma-bearing germ free mice, mice showed improved tumor control, 
increased T cell responses, and greater efficacy of anti–PD-L1 therapy. Routy et 
al. show that non–small cell lung cancer, renal cell carcinoma, and urothelial 
carcinoma patients who had a prior exposure to antibiotics had poor response to 
anti-PD-1 therapy. The antibiotic treatment disturbed the specific “good” bacterial 
clades (Akkermansia, Faecalibacterium, and Bifidobacterium), driving resistance 
to anti-PD-1 therapy. Together these studies suggest that composition and 
diversity of gut microbiota are critical factors mediating response to 
immunotherapy, and imbalance in gut flora composition could drive resistance to 
therapy. 
1.2.4: Upregulation of alternative immune checkpoints  
Persistent tumor antigen availability exhausts T cells in the TME, and 
exhausted T cells upregulate multiple inhibitory receptors like CTLA-4, PD-1, PD-
L1, TIM3, LAG3 and VISTA. Paradoxically, these receptors also represent 
activated T cells, and evidences suggest that these receptors are regulated by 
distinct non-redundant mechanisms.  We have shown earlier that anti-CTLA-4 
21 
 
 
 
blockade therapy increased PD-1 expression on tumor infiltrating T cells leading 
to acquired resistance to CTLA-4 therapy (94,95). We and others have shown that 
combining anti-CTLA-4 therapy with anti-PD-1 therapy provides synergistic 
survival benefit (8,9,94,96). This suggests that alternative checkpoint molecules 
mediate resistance to therapy, and targeting multiple checkpoint molecules might 
increase survival rates. In genetically engineered mouse models of lung 
adenocarcinomas and stage IV lung adenocarcinoma patients, Kayoma at el. have 
shown that upregulation of T-cell immunoglobulin and mucin domain-3 (TIM-3) on 
TIL was a mechanism of adaptive resistance to anti-PD-1 therapy(97). Similarly, 
in a murine HNC tumor model and human HNSCC tumors, TIM3 was upregulated 
in a PI3K/Akt-dependent manner during PD-1 blockade and sequential addition of 
anti-Tim-3 antibodies demonstrated significant antitumor activity. Gao and 
colleagues have shown that anti-CTLA-4 therapy increases level of PD-L1 and 
VISTA on TIL and macrophages as a compensatory inhibitory pathway in prostate 
and melanoma patients (95). These studies support an idea of a circuit of 
compensatory alternative checkpoint signaling as a potential escape mechanism 
to checkpoint blockade therapy.  
  1.2.5: Angiogenesis and immune trafficking  
To meet the continuously growing energy demand, tumors create a 
proangiogenic milieu, which signals tumor associated blood vessel formation 
(neovascularization). Tumor associated blood vessels and the 
immunosuppressive proangiogenic milieu limits the beneficial effects of cancer 
immunotherapies. Vessels development in normal tissue is a tightly controlled 
process, regulating blood supply to the tissue and helping in immune surveillance 
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through extravasation of lymphocytes. On the other hand, tumor blood vessels are 
developed abruptly so they harness structural abnormalities including 
heterogeneous distribution, tortuosity, dilation, and inadequate perivascular 
coverage. Abnormal tumor vasculature limits the extravasation of tumor-specific 
CD8 T cells and also affects their survival, proliferation and effector function. 
Additionally, tumor vasculature promotes immunosuppressive microenvironments 
by allowing infiltration of suppressive cells like tumor associated macrophages 
(TAMs), myeloid derived suppressor cells (MDSC) and regulatory T cells (Treg) 
(98). Vascular endothelial growth factor (VEGF), which is a master regulator of 
tumor angiogenesis, also functions as an immunosuppressive factor.  VEGF 
promotes expression of the death mediator Fas ligand (FasL, also called CD95L) 
on tumor vasculature which is known to induce receptor mediated death of CD8 T 
cells and  to increase infiltration of Treg (98). VEGF also regulates the expression 
of adhesion molecules like intercellular adhesion molecule–1 (ICAM-1) and 
vascular cell adhesion molecule–1 (VCAM-1) which negatively affect T cell 
infiltration and function (99,100).  Elevated VEGF in the TME inhibits T cell immune 
responses (101), suppresses DC maturation (102), and promotes Treg 
suppressive function (98,103). Additionally, VEGF also recruits MDSCs, which 
serve as an extra source of immunosuppressive cytokines and chemokines in TME 
(104-108).  Moreover, therapeutically blocking the VEGF/VEGFR2 signaling 
pathway could reverse immunosuppression in TME (101,103). In preclinical 
studies, Schmittnaegel et al. and Allen et al. showed that targeting tumors with a 
combination of checkpoint blockade immunotherapy and antiangiogenic 
treatments produced synergistic antitumor responses (109,110).  This suggests 
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that tumor proangiogenic process is immunosuppressive in nature and one of the 
mechanisms driving resistance to immunotherapy (109,110).  
1.3: Overcoming mechanisms of resistance 
  
From above, it is clear that tumors use multiple evasion mechanisms to 
drive resistance to immunotherapy. The resistance mechanisms could be primary 
or acquired during therapy. These mechanisms also vary among different tumor 
types and patients, which makes it important to identify patient-specific 
mechanisms to therapeutically target them.  There are various efforts to use the 
knowledge of tumor evasion mechanisms to predict immunotherapy response and 
apply the knowledge gained to target patient-specific resistance mechanisms. 
Characterizing the tumor mutational landscape along with MHC class-I 
prediction algorithms to predict the neoantigen burden has shown promise in the 
clinic to formulate patient-specific vaccines. Tumors with higher mutational load 
correlate with more tumor specific CD8 T cell infiltration and are more likely to 
respond to checkpoint therapy. Immune phenotyping using flow cytometry or 
CyTOF and immunogenomics are also identifying tumors with high immune 
infiltrate (immunologically “Hot” tumors), as being more likely to respond to 
immunotherapy. The immunologically “cold” tumors could be then targeted to 
increase their immune infiltrates and make them sensitive to therapy. Immune 
phenotyping has also yielded important information about the functional status of 
anti- and pro-tumor immune infiltrates such as alternative checkpoints molecules 
on T cells, arginase and IDO.  
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The majority of approaches focus on therapeutically targeting one of the 
resistance mechanisms in combination with immunotherapy to overcome 
resistance associated with treatment. The knowledge obtained (111,112) from 
mutational profiling of tumors is used to design personalized neoantigen vaccines 
to increase the immune infiltrates in resistant tumors. The most extensively studied 
and successful strategies to target immunotherapy resistance across various 
tumor types are combining antibodies against two immune checkpoint molecules 
(47,94). Combining PD-1 and CTLA-4 therapies elicit long term survival benefits 
in melanoma, which can last for years (8,9,113). 
Cancer neoantigen vaccines have shown promising results in early clinical 
studies breaking resistance to checkpoint immunotherapies (NCT02113657) 
(26,114-116). Radiation therapy can increase mutational burden in cancer cells, 
and combination therapy has been shown to increase the T cell response and 
shows promise results in early clinical trials (NCT01449279) (117,118).  Another 
successful strategy to improve neoantigen burden and turn immunologically “cold” 
tumors into “hot” tumors is combining oncolytic viruses with immunotherapy 
(NCT03153085, NCT02879760, NCT02798406 and NCT03259425) (119). Prime 
examples of targeting the immunosuppressive tumor microenvironment are 
targeting immunosuppressive myeloid cells with phosphoinositide 3-kinase γ 
Inhibitor (IPI549- NCT02637531) (120), CSF1R Inhibitor (PLX3397-
NCT02452424) (121), Indoleamine 2,3-dioxygenase inhibitors (Indoximod-
NCT02073123 (77) and Epacadostat-NCT03291054) (122,123), STING agonists 
(NCT03172936) (124) and arginase inhibitors (INCB001158-NCT02903914) 
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(125). Drugs targeting tumor hypoxia (Evofosfamide –TH-302 and Metformin) have 
shown synergistic pre-clinical benefit when combined with immunotherapy (56,57) 
and are under clinical investigation (NCT03098160 and NCT03048500).   
Targeting tumor metabolism can be self-defeating since it can also negatively 
impact anti-tumor immunity. However, in CT26 colon carcinoma tumors, treatment 
with a combination of glutaminase inhibitor (CB-839) and anti-PD-1 or anti-PD-L1 
enhanced the anti-tumor activity (126) and is under clinical evaluation 
(NCT02771626).  
Several preclinical studies have demonstrated that composition and 
diversity of microbiota can mediate resistance to immunotherapy, and that feeding 
the “good” bacteria improves the efficacy of therapy (80,81,84-88,91-93). This 
approach is now under clinical evaluation (NCT03353402).   Anti-angiogenic 
treatment can have a substantial effect on anti-tumor immunity and has shown 
potential synergy when used with immunotherapy (109,110). This approach is also 
currently being tested in the clinic (NCT0285425 and NCT03167177).   
There are ongoing efforts to understand the mechanisms that regulate anti-
tumor T cell responses and resistance to immunotherapeutic pressure, including 
translation of preclinical insight to the clinic and taking clinical observations back 
to the bench. To expand the number of patients who can benefit from 
immunotherapy, a comprehensive understanding of primary, adaptive, and 
acquired resistance to immunotherapy is required. Overall, targeting resistance 
mechanisms with therapeutic agents has shown promising preclinical results and 
is being evaluated in the clinic.  
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1.4: Pathophysiology of immune related adverse effects (IRAEs) 
Increasing the efficacy of T cell checkpoint modulating antibody 
immunotherapy either by improving benefit as a monotherapy or by combining with 
therapeutic agents targeting resistance could also lead to immune related adverse 
effects (IRAEs). This leads to host-specific T cell response targeting dermatologic, 
gastrointestinal, hepatic, endocrine, and other tissues. Steroids are used in the 
clinic to manage these immune related adverse events (IRAEs), but steroids are 
immunosuppressive and may compromise the anti-tumor response. Detailed 
understanding of these mechanisms will help design new therapeutic strategies to 
overcome resistance to immunotherapy without inviting unwanted immune related 
side effects.  
Checkpoint proteins are critical players in preventing autoimmunity by 
constraining hyperactive responses through central (during T cell development in 
thymus) and peripheral tolerance (tissue specific self-antigen outside the thymus). 
Genetic polymorphisms in checkpoint proteins break self-tolerance and can lead 
to various autoimmune diseases. Polymorphisms in checkpoint proteins such as   
CTLA-4, PD-1 and PD-L1 are associated with various autoimmune toxicities such 
as thyroiditis (127,128), Graves’ disease (127,128), diabetes mellitus 
(127,129,130), rheumatoid arthritis (128), celiac disease (129,131), myasthenia 
gravis (132), and systemic lupus (127,133-135). Tumors escape immune attack by 
exploiting the co-inhibitory immune checkpoint axis on T cells in order to make 
them anergic, exhausted, and incapable to complete anti-tumor effector functions. 
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Targeting these molecules with therapeutic antibodies that block co-inhibitory 
immune checkpoint molecules, such as CTLA-4, PD-1, TIM3 and PD-L1 reactivate 
T cells and restore their capacity to mediate antitumor activity. T-cell-specific anti-
tumor immune responses can also be reactivated with agonist antibodies targeting 
co-stimulatory molecules such as: 4-1BB (CD137, TNFRSF9, tumor necrosis 
factor receptor superfamily member 9), OX40 (CD134, TNFRSF4, tumor necrosis 
factor receptor superfamily member 4) and glucocorticoid-induced tumor necrosis 
factor receptor (GITR). However, a disruption of immunomodulatory receptors 
(checkpoint receptors and co-stimulatory receptors) can break T cell tolerance and 
lead to hyperactive immune responses against self-tissues and organs such as 
skin, gastrointestinal, hepatic, pulmonary, mucocutaneous, and endocrine 
systems. The hyperactive immune system exerts collateral damage on self-
tissues, which is termed ‘immune-related adverse events’ (IRAEs). This section 
discuses pathophysiology of organ specific IRAEs associated with 
immunomodulatory antibodies.  
1.4.1: Dermatological toxicities 
  The most common lesions associated with immunomodulatory antibodies 
are rash, vitiligo, and alopecia areata. The most commonly reported rashes are 
maculopapular, papulopustular, Sweet’s syndrome, follicular, and urticarial 
dermatitis. Meta-analysis conducted on 57 case reports and 24 clinical trials 
showed that 44% of the patients on αCTLA-4 therapy (Ipilimumab and 
tremelimumab) had reported some form of dermatological toxicity (136). A pooled 
analysis on melanoma patients who received αPD-1 therapy showed skin related 
toxicities in 35-39 % of patients (137). In a study comparing safety and efficacy of 
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αCTLA-4 and αPD-1, 25-31 % patients on Pembrolizumab (αPD-1) and 4% of 
patients on (αCTLA-4) reported Vitiligo (138,139). The histopathologic features of 
dermatitis are represented by infiltration of CD4 T cells and eosinophils in the 
dermis. Immune related dermatitis in the clinic is treated with corticosteroids 
(139,140).    
1.4.2: Mucosal and gastrointestinal toxicities 
Diarrhea and colitis are the most common side effects associated with 
immunomodulatory antibody treatment, which, if not managed, can lead to severe 
complications such as intestinal perforation (141). Diarrhea and colitis are more 
common with anti CTLA-4 compared to PD1/PD-L1 blockade (138,142,143). More 
than 30% of patients who received Ipilimumab reported grade ≥2 diarrhea 
(138,143) and about 10% of  patients also experience severe grade colitis and 
diarrhea (143). On the other hand, 5-10% of patients on PD-1 (Nivolumab and 
Pembrolizumab) therapy reported colitis (138,144,145). Histological features of 
CTLA-4 mediated colitis are characterized by neutrophilic inflammation, 
lymphocytic inflammation, or combined neutrophilic and lymphocytic inflammation 
(142,146). Lymphatic inflammation is characterized by increases in CD8 effector 
T cells in intestinal epithelium and CD4 effector cells in lamia propria (142,146). 
Immune modulatory antibody-induced diarrhea is managed by corticosteroids, with 
budesonide for grade I-II colitis (141) and anti-TNFα antibody (infliximab) for 
severe colitis (141,146).  
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1.4.3: Hepatotoxicity 
Most immunomodulatory antibodies cause asymptomatic increases in 
serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
enzymes, which is often attributed to hepatitis. These enzyme elevations could 
also be due to viral infections (hepatitis A, B or C), presence of a tumor, or liver 
metastasis, which makes it difficult to distinguish immune-related hepatitis.  Less 
than 5% of patients reported elevated transaminase levels on anti CTLA-4 in four 
different studies, and transaminitis was resolved without administration of 
immunosuppressive medications when αCTLA-4 therapy was temporarily withheld 
(143,147-149). Advanced hepatocellular carcinoma (HCC) patients on Nivolumab 
(anti PD-1) therapy showed elevated AST in 10% and ALT in ≥ 17% of patients 
(150). Anti PD-L1 (MPDL3280A) antibody treatment in non-small cell lung cancer 
(NSCLC) resulted in transaminitis in less than 5% of patients (151).  Clinical 
development of 4-1BB agonist antibodies, in contrast, has been hampered by 
hepatic inflammation since about 15% of patients on Urelumab (4-1BB agonist 
antibodies) had grade ≥2 hepatitis (152,153). The early clinical trials of Urelumab 
were terminated and withdrawn due to an unusually high incidence of grade 4 
hepatitis (152,153). Steroids are commonly used to manage immune related 
hepatitis. As 4-1BB induced hepatitis is triggered by myeloid cells, steroids might 
not be very effective in managing hepatitis in this setting (25).   
1.4.4: Endocrine toxicities 
 Immune-related toxicities affecting endocrine glands are more common in 
anti-CTLA-4 therapy compared to PD-1/PD-L1 blockade and are mainly 
characterized by development of hypophysitis and thyroid dysfunction (140,154-
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157).  Hypophysitis, or inflammation of the pituitary gland, affects up to 10% of  
patients on anti-CTLA-4 therapy and 1-6% of patients on PD-1/PD-L1 blockade 
(140,154-157). Hypophysitis can affect the entire endocrine system including the 
pituitary-hypothalamic axis, pituitary–thyroid axis, pituitary–gonadal axes, and 
pituitary–adrenal axes (140,154-157). This makes hypophysis difficult to diagnose 
since symptoms can be nonspecific. Diagnosis involves biochemical screening of 
various endocrine hormones such as prolactin (PRL), thyroid-stimulating hormone 
(TSH), thyroxine (T4), luteinising hormone (LH), follicle-stimulating hormone 
(FSH), adrenocorticotropic hormone (ACTH), and cortisol (28,139). Pituitary 
hormone inefficiency is treated with glucocorticoid replacement therapy, and in 
some patients, there is need for life-long therapy (140,154-157). Pituitary 
endocrine cells ectopically express CTLA-4 on their surface (158). Anti CTLA-4 
antibodies bind to pituitary endocrine cells and serve as sites for complement 
activation which leads to an inflammatory cascade (158,159).  Caturegli at el. also 
highlight the role of T cell mediated inflammation in CTLA-4 induced Hypophysitis 
(160).  
 Thyroiditis followed by hypothyroidism is also reported with anti- CTLA-4, 
PD-1 and PD-L1 therapies, which is managed by thyroid hormone replacement 
therapy. In some incidences, Grave’s disease, which may arise due to 
development of anti-TSH antibodies, has been reported on anti CTLA-4 therapy.  
1.4.5: Other rare toxicities  
Pneumonitis, or inflammation of lung parenchyma, is more common with 
PD-1/PD-L1 blockade (16,144). It has been reported in about 10% of patients who 
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received either PD-1 or PD-L1 antibodies (16,144). Immune related pneumonitis 
can be life threatening and resulted in three treatment related death in early 
Nivolumab studies (161). Although low grade immune-related pneumonitis could 
be managed with systemic steroids, severe cases require other forms of 
immunosuppression such as infliximab, or cyclophosphamide (139,162). Elevation 
of pancreatic enzymes lipase and amylase has been reported in response to both 
CTLA-4 and PD-1 blockade. Similarly, uveitis, nephritis, and neurotoxicities have 
been reported in patients receiving both anti-PD-1 and anti-CTLA-4 therapy 
(139,143,163-168).  Most immune related rare toxicities do not have required lab 
tests outside of clinical trials, which makes it challenging to manage them in clinic.  
Steroids are generally the first choice to manage immune related uveitis, nephritis, 
pancreatitis, cardiotoxicites and neurotoxicities (139). 
  Mechanisms underlying immune-related adverse events (IRAEs) are still 
largely undefined. Research in the field of tumor immunotherapy focuses on 
improving the efficacy of therapies to expand clinical benefit across different tumor 
types while eliminating unwanted side effects.  The second chapter of the 
dissertation focuses on understanding the molecular mechanisms of acquired 
resistance to triple (αCTLA-4, αPD-1 and αPD-L1) combination of checkpoint 
immunotherapy. The third chapter of the dissertation focuses on characterizing 
mechanisms of immune related hepatotoxicity associated with 4-1BB agonist 
antibodies.  
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Chapter 2: Immunotherapy Resistance  
 
 
 
Melanoma Evolves Complete Immunotherapy 
Resistance through Acquisition of a Hyper 
Metabolic Phenotype 
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2.1: Abstract 
Despite the success of T cell checkpoint blockade antibodies in treating an 
array of cancers, a majority of patients still fail to respond to these therapies, or 
respond transiently followed by a relapse of the malignancy. The molecular 
mechanisms which drive the lack of response to checkpoint blockade, whether 
pre-existing or evolved when on therapy, remain unclear.  In order to address this 
critical gap in clinical knowledge, we established a murine model of melanoma 
designed to elucidate the molecular mechanisms underlying immunotherapy 
resistance. Through multiple in vivo passages, we selected a B16 melanoma tumor 
line that evolved complete resistance to combination blockade of CTLA-4, PD-1, 
and PD-L1, which cures ~80% of mice bearing the parental tumor. Using gene 
expression analysis, and immunogenomics, we determined the adaptations 
engaged by this melanoma to become completely resistant to T cell checkpoint 
blockade immunotherapy. Acquisition of immunotherapy resistance by these 
melanomas was driven by the coordinated upregulation of the glycolytic, 
oxidoreductase, and mitochondrial oxidative phosphorylation pathways to create a 
metabolically hostile microenvironment wherein T cell functions are suppressed. 
We have observed and validated the upregulation of these pathways in a cohort 
of melanoma patients resistant to dual checkpoint blockade.  Additionally, we 
employed MRI imaging to visualize in real time the metabolic changes in resistant 
tumors of mice.  Clinical application of this technique could provide a much-needed 
non-invasive tool to predict sensitivity of patients to immunotherapy. Together 
these data indicate that melanoma tumors can evade by adapting a hyper 
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metabolic phenotype, melanoma tumors can evade T cell immunity and achieve 
resistance to T cell checkpoint blockade. 
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2.2: Introduction 
T cell checkpoint blockade immunotherapies such as anti-cytotoxic-
lymphocyte antigen-4 (αCTLA-4) and anti-programmed-death-1 and its ligand 
(αPD-1/αPD-L1) antibodies have shown long term survival benefits across several 
tumor types including melanoma (10,47,113,169), renal cell carcinoma (RCC), 
bladder cancer, hematological malignancies and non-small cell lung cancer 
(NSCLC). Despite these advances, a significant percentage of patients show 
intrinsic or naturally acquired resistance to immune checkpoint blockade 
antibodies, causing patients to have limited or no response to therapy. Moreover, 
there is no biomarker which can accurately predict clinical response to checkpoint 
blockade immunotherapy.  Many non-immunogenic tumors such as pancreatic, 
and prostate cancers have shown little or no response to immune checkpoint 
antibodies.  This study addresses two major goals of the field; first, to increase the 
number of patients who could benefit from immune checkpoint blockade antibodies 
and second, to identify prognostic biomarkers that could be use predict response 
to checkpoint blockade immunotherapy. 
In order to extend the curative potential of immunotherapy to a larger subset 
of patients, we must first understand the cellular and molecular mechanisms that 
tumors engage to escape immunotherapy and drive relapses. Several efforts are 
ongoing to understand the mechanisms of acquired resistance to checkpoint 
immunotherapy and extend this knowledge to identify prognostic biomarkers. 
Immune escape mechanisms that tumors engage to hide from immune attack have 
been extensively studied (3-5,170,171) even before the approval of the first 
36 
 
 
 
checkpoint blockade antibody. Until now, most of the research addressing 
checkpoint blockade therapy resistance mechanisms focused on the upregulation 
of alternative immune checkpoint proteins such as TIM3 (97,172) and VISTA (95). 
Mutational load (49,111,173), neoantigen burden (173), and copy number loss of 
components of the antigen presentation machinery (112,174) by tumor cells have 
also been previously described as mechanisms driving resistance to αPD-1 and 
αCTLA-4 monotherapies. Despite these advances, the basis for partial or lack of 
response and mechanisms of resistance to different checkpoint blockade 
immunotherapies remains to be elucidated. Additionally, little is known about the 
transcriptomic states of tumor cells that can influence sensitivity to the immune 
system and whether this intrinsic signaling can play an important role in checkpoint 
blockade resistance.  To address this critical gap in knowledge, we established a 
novel mouse model of melanoma. The model relies on the ‘cancer immunoediting’ 
theory (5), which states that the immune system, while protecting the host from 
tumor development, can exert evolutionary pressure which simultaneously drives 
selection of select for immune-resistant tumor strains. We therefore used the ‘in 
vivo serial passage approach’ originally developed by Fidler et. al. to select 
melanoma clones with increasing metastatic potential to the lung (e.g. B16-F10) 
(175-177), in this case selecting melanoma clones with increasing resistance 
checkpoint blockade immunotherapy. Based on gene expression profiling of 
immunotherapy resistant clones, we hypothesized that tumor cells evade response 
to immunotherapy by the coordinated upregulation of aerobic glycolysis, 
oxidoreductase, and mitochondrial mediated oxidative phosphorylation pathways, 
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which creates a hostile metabolic microenvironment in which cytotoxic CD8 T cells 
are rendered dysfunctional.   
To experimentally validate the roles each of the identified metabolic 
pathways, gene expression analysis was followed by a seahorse flux assay 
(glycostress and mitostress assay) and NMR metabolomics analysis which confirm 
the upregulation of glycolysis and mitochondrial oxidative phosphorylation.  In 
hypermetabolic, resistant tumors, CD8 T cell function was profoundly suppressed. 
We have also validated upregulation of these pathways in a cohort of melanoma 
patients who failed dual checkpoint blockade therapy. Overall, our data 
demonstrate that these resistant tumors upregulate glycolysis, oxidoreductase and 
mitochondrial mediated oxidative phosphorylation to evade the response to anti-
CTLA-4, anti-PD-1 and anti-PD-L1 immunotherapies. 
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2.3: Methods 
2.3.1: Mice 
Four to eight week old Male C57BL/6J (000664) and Rag1 knock out mice 
were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). The 
mice were cared for in a pathogen-free facility at our institution, which is fully 
accredited by the Association for Assessment and Accreditation of Laboratory 
Animals Care International. All animal experiments were performed according to 
the protocols approved by the Institutional Animal Care and Use Committee. 
2.3.2: Therapeutics antibodies 
Anti CTLA-4 (9H10), anti-PD-1 (RMP1-14), anti-PD-L1 (10F.9G2) anti CD-
40 (FGK4.5) and anti-VEGF (DC101) were purchased from BioXCell (West 
Lebanon, NH, USA) and administered intraperitoneally.  
2.3.3: Patient cohort 
Surgical samples were acquired from metastatic melanoma patients treated 
with anti-CTLA-4 (ipilimumab) and/or anti-PD-1 (pembrolizumab or nivolumab) at 
the UT MD Anderson Cancer Center between April 2014 and September 2015 on 
IRB protocol 2012-0846 prior to therapy or at time of progression (Table 2.1). 
Clinical response was evaluated by RECIST 1.1 (173,178). 
2.3.4: Cell lines 
The B16/BL6 cell line was originally obtained from I. J. Fidler (MD Anderson 
Cancer Center, Houston, TX). The B16-sFlt3L-Ig (FVAX) and B16-tdTomato cell 
lines have been described previously (94). The cells were maintained in RPMI 
media with 10% Fetal Bovine Serum (FBS).  
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2.3.5: Harvesting B16 melanoma 
To harvest the mouse tumors, tissues were treated with 0.25 mg ml−1 
collagenase A (Sigma-Aldrich (St. Louis, MO, USA) and 25 U ml−1 DNase (Roche 
Diagnostics, Indianapolis, IN, USA) for 20 min at 37°C; the dissolved cells were 
then passed through a plastic mesh. The resulting dissociated cells were collected 
by centrifugation and washed twice in phosphate-buffered saline (PBS). The cells 
were then cultured and/or used for flow cytometry analysis and/or flow sorting. 
2.3.6: Generation of checkpoint blockade immunotherapy–resistant 
melanoma cells   
We initially implanted 15 mice with 2.5 x 104 B16/BL6-td cells 
subcutaneously and treated then with a combination of triple T cell checkpoint 
blockade inhibitors. Specifically, on days 3, 6, and 9, post implantation, the mice 
were vaccinated with 1 x 106 irradiated (150 Gy) FVAX cells on the contralateral 
flank and treated with a combination of anti-CTLA-4 (100 μg of 9H10), anti-PD-1 
(250 μg of RMP1-14), and anti-PD-L1 (100 μg of 10F.9G2). Non-responder mice, 
who developed tumors regardless of treatment, were euthanized when tumors 
reached 200-500 mm3 and their tumors were harvested. Tumors from all non-
responder mice were pooled and a cell line (3I-F1) was generated. The cell line 
(3I-F1) was then used to in a new set of 15 mice (second cycle) followed by the 
same immunotherapy regimen. For the second cycle and all subsequent cycles, 
only 1 x 104 were implanted. The decrease in tumor cell number compared with 
the initial challenge was designed to distinguish true resistance from experimental 
variation. We repeated the serial passages until ≥90% of the animals became 
resistant to the therapy. B16 melanoma cell lines were called 3I-F1, 3I-F2, 3I-F3, 
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and 3I-F4 (Resistant), respectively. For the untreated control group, we implanted 
5 mice with parental tumor cells and with tumor cells from each cycle of selection. 
2.3.7: Treatment strategies and monitoring tumor growth   
Wild type mice were subcutaneously implanted with 2.5 x 104 B16/BL6-td 
or 3I-F4 cells and treated with a combination of triple checkpoint blockade 
inhibitors. Specifically, on days 3, 6, and 9, mice were vaccinated with 1 x 106 
irradiated (150 Gy) FVAX cells on the contralateral flank and treated with a 
combination of anti CTLA-4 (100 μg of 9H10), anti PD-1 (250 μg of RMP1-14), and 
anti PD-L1 (100 μg of 10F.9G2). TNF superfamily agonist antibodies, anti 41BB 
(150 µg of 3H3) and anti CD40 (100 µg of FGK4.5) were given intraperitoneally on 
days 3, 6 and 9.  Anti-VEGF (100 μg of DC101) was administered intraperitoneally 
on days 6, 9 & 12. Metformin (50 mg/kg; every other day) and 2DG (500mg/kg; 
daily) were given intraperitoneally beginning one day post tumor challenge. For 
metformin drinking water cohorts, mice were given 1g/L metformin drinking water 
post tumor implantation. LDH inhibitor (4mg/kg), IPI549 (15mg/kg) and Oxphos 
inhibitors (5mg/kg) were prepared in polyethylene glycol (PEG) base as per 
manufacturer’s instructions and given through oral gavage every day post tumor 
implantation. On days 3, 4, 5, 6 and 7 post tumor challenge, TH302 (50mg/kg) was 
given intraperitoneally and STAT3 ASO (50mg/kg) was given subcutaneously on 
the contralateral flank. Tumors were measured every other day and a death event 
was counted when tumor volume reached 1000 mm3 or a mouse dies because of 
metastasis.  
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2.3.8: RNA extraction  
Tumors were harvested from mice and sorted using flow cytometry based 
on the td-tomato fluorescence into tumor cells and cells of the tumor 
microenvironment (non-tumor), which included both CD45 positive and CD45 
negative populations. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, 
MD). 
For human patients, the presence of tumor was confirmed by a pathologist, and 
total RNA was extracted from the tumor tissue using the RNeasy Mini kit. (Qiagen, 
MD)  
2.3.9: Microarray analysis  
Tumor cells and non-tumor cells of the microenvironment were sorted by 
flow cytometry and RNA was isolated from both as described above. Microarray 
analysis was done on both tumor cells and microenvironment from two 
independent RNA samples from parental tumors and four independent RNA 
samples from 3I-F4 tumors. Each RNA sample was isolated from tumors pooled 
from three mice.  Microarray analysis was also done on RNA isolated from patients’ 
tumor biopsies. Microarray analysis was conducted using MouseRef-8 and 
HumanHT-2 bead chip arrays (Ilumina) respectively.  
2.3.10: Bioinformatics analyses 
Microarray data was normalized as per manufacturer’s instructions and 
processed in R (version 3.4.1). Low intensity probes that were not significantly 
expressed above the background level (detection p-value≥0.05 in at least one of 
the samples) were excluded.  Differential expression between resistance and 
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parental for tumor, and respectively for microenvironment was determined by a 
fold-change in absolute value equal or greater to 1.1  and a p-value obtained from 
the moderated t-statistic from LIMMA package less than 0.05.  To support visual 
data exploration, we employed R to generate volcano plots, as well as heatmaps 
making use of the heatmap.2 function of gplots library.   
Gene set enrichment analysis (GSEA) and ingenuity pathway analysis (IPA) 
were applied to the data sets as an unbiased bioinformatics analysis in order to 
compare resistant tumors with parental tumors and responder patients with non-
responder patients.  
2.3.11: Extracellular flux analyses 
Resistant and parental cell lines were seeded at a density of 25,000 cells 
per well 24 hr prior to the assay. Oxygen consumption rate (OCR) and extra cellular 
acidification rate (ECAR) were measured as per the manufacturer’s protocols on 
an XF96 Analyzer (Seahorse Biosciences).  
2.3.12: Immunofluorescence staining and imaging 
In order to image hypoxia, mice were administered Pimonidazole 
(Hypoxyprobe, Burlington, MA) intravenously thirty minutes prior to euthanasia so 
that hypoxia could be imaged in tumor sections by immunofluorescence staining 
with anti-pimonidazole adduct FITC conjugated antibody (Hypoxyprobe, 
Burlington, MA). Mouse tissues were collected and embedded in Tissue-Tek® 
OCT Compound (Sakura, Torrance, CA). The embedded tissues were then flash 
frozen in liquid nitrogen and sectioned at the MD Anderson Histology Core. The 
sectioned tissue was fixed with acetone for 10 min, permeabilized with the FoxP3 
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staining kit (eBioscience, San Diego, CA) for 10 min, and blocked with Superblock 
(Thermo Fisher) for 15 min at room temperature. The samples were stained with 
antibodies in 2% bovine serum albumin, 0.2% Triton-X100 in PBS at room 
temperature for 30 min and, after being washed in PBS, mounted with Prolong® 
Gold anti-fade reagent (Invitrogen, Carlsbad, CA). Fluorescence microscopy was 
performed using a TCS SP8 laser-scanning confocal microscope equipped with 
lasers for 405nm, 458nm, 488nm, 514nm, 568nm, and 642nm wavelengths (Leica 
Microsystems, Inc., Bannockburn, IL). 
2.3.13: Extraction of metabolites and NMR analysis 
Cells were trypsinized and washed twice with phosphate buffer saline (PBS) 
and flash frozen in liquid nitrogen. Tumors from mice with and without 
immunotherapy treatments were collected on day 12-16 post implantation and 
flash frozen on liquid nitrogen. Cells were counted and tumor tissues were weighed 
before extraction of metabolites. Cells and tumor tissues were homogenized. The 
homogenized tissues/cells were added with 2:1 methanol and ceramic beads. The 
tissues/cells were then vortexed for 40 – 60 seconds followed by freezing in liquid 
nitrogen and thawing on ice.   Water soluble proteins and other biopolymers were 
precipitated in methanol solvent leaving the small molecular weight metabolites in 
the solution which were then extracted using ultra-centrifuge. The remaining 
residual solvent was removed by overnight lyophilization.   
The lyophilized sample was dissolved in 800 µl of 2H2O and centrifuged at 
10,000 rpm. The 600 µl of sample was added with 40 µl of 8 mM 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) before acquisition on  NMR.  The NMR data 
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were collected on Avance Bruker spectrometer operating at 500 MHz poton (1H) 
resonance frequency, equipped with cryogenically cooled triple resonance (1H, 
13C, 15N) TXI probe. All one dimensional (1D) 1H NMR spectra were acquired with 
suppressed solvent (water) signal achieved by pre-saturation during longitudinal 
relaxation time. The inter-scan delay of 6 seconds is used to rule out the 
longitudinal relaxation related signal attenuation. The 900 radio frequency (r.f) 
pulse of 12 µs, spectral width of 8,000 Hz and  256 transients were used to acquire 
the 1D 1H NMR.  All spectra were processed in topspin 3.1 and metabolites are 
assigned with the help of Chenomx and Human Metabolomics Database (HMDB).  
The intensities of metabolites were taken with respect to NMR reference 
compound of 0.5 mM 2, 2 Dimethyl-2-Silapentane-5-sulfonate-d6 (DSS) appearing 
at 0 ppm. And then all the intensities (area under the curve) of the metabolites 
were normalized to the cell numbers and tumor mass. The normalized intensities 
were used to calculate the Z score expressing relative expression of metabolite in 
resistant tumors/cell lines compared to parental tumors/cell line.  
2.3.14: Hyperpolarized pyruvate to lactate flux imaging of tumors  
Hyperpolarization is a process that uses microwave irradiation to transfer 
electron polarization to nuclei at temperatures as low as ~1.3 K leading to an 
increased signal intensity of nuclei (13C, 29Si etc.) of about 10,000 compared to 
the conventionally observed signal. The mixture of 20 µl 1-13C, 10 µl of 15 mM 
trityl radical OX63 and 0.4 µl Gd2+ was hyperpolarized for an hour with microwave 
irradiation at 94 GHz at low temperature 1.5 K in Oxford Hypersense instrument. 
The hyperpolarized pyruvate was dissolved at high temperature in 4 ml of 
TRIS/EDTA buffer at physiological pH 7.8 to a final concentration of 80 mM of 
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pyruvate. 200 µl of the solution was injected into the mice via tail vein injection  
which was in horizontal bore 7 T Bruker MR Scanner (179). 
The anatomical proton image and 13C Magnetic Resonance Spectroscopy 
(MRS) were acquired using surface transceiver 13C-1H coil (Doty Scientifics). 
Anatomical images of coronal, axial and sagittal were acquired with T2 weighted 
Rapid Imaging with Refocused Echo (RARE) sequence to determine the size and 
location of tumor in mice models. The 13C enriched urea phantom was used as 
spectroscopic reference as well as being used to locate the tumor. The single pulse 
Fast Low Angle Shot (FLASH) was used to acquire 1D 13C magnetic resonance 
spectroscopy (MRS) with repetition time of 2 seconds, flip angle 200, image size 
2048 X 90 and single slice of thickness 5-10 mm and acquired over a period of 
180 seconds (179). 
2.3.15: Flow cytometric characterization of resistant tumors 
Following density gradient separation, samples were fixed using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience) and then stained 
with up to 18 antibodies at a time from Biolegend, BD Biosciences, eBioscience, 
and Life Technologies.  Flow cytometry data was collected on a custom 5-laser, 
18-color BD LSR II cytometer and analyzed using FlowJo Version 7.6.5 
(Treestar)(25,26).   
For metabolic characterization of CD8 T cells, fluorescently labeled glucose 
(NBDG) was intravenously injected in tumor bearing mice 30 minutes prior to 
sacrificing mice for tumor harvest.  
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2.3.16: Retroviral vectors and virus production  
Murine PGAM2 and ADH7 cDNAs were cloned into the pMG-rtNGFr 
retroviral vector. This vector resembles pGC-IRES except that for a truncated form 
of rat p75 nerve growth factor receptor (rtNGFr) is used for selection (30). 
Recombinant virus production and infection were performed as described (180).  
2.3.17: Statistical analysis 
All statistics were calculated using Graphpad Prism Version 6 for Windows.  
Statistical significance was determined using a two-tailed Student’s t test applying 
Welch’s correction for unequal variance. Graphs show mean ± standard deviation 
unless otherwise indicated.  P-values less than 0.05 were considered significant.  
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2.4: Results  
2.4.1: B16/BL6 melanoma cells acquired resistance to checkpoint blockade 
immunotherapy through serial in vivo passage 
In current preclinical tumor models it is difficult to distinguish between mice 
that are sensitive (responders) and resistant (non-responders) to immunotherapy. 
Moreover, current tumor models do not allow for easy separation of tumor cells 
from non-tumor microenvironment for downstream genome and transcriptomic 
analysis. To understand tumor intrinsic molecular mechanisms of resistance to 
checkpoint immunotherapy, we generated B16 melanoma clones that have 
developed resistance to the combination of αCTLA-4, αPD-1, and αPD-L1 
immunotherapy through serial in vivo passaging for increasing resistance. After 
four in vivo passages, we selected a B16 melanoma tumor line 3I-F4 (Resistant) 
that had evolved almost 100% resistance to combination co-inhibitory blockade, 
which could initially cure 80% of the mice (Fig. 2.1A & 2.1B). The tumor became 
increasingly aggressive after each subsequent passage and grew progressively, 
even in the presence of strong immunotherapeutic pressure. This model not only 
allowed us to enrich the genetic signature of resistance, but also provided the 
opportunity to separate tumor cells away from tumor microenvironment before 
analysis since B16 melanoma clones were transduced to express the fluorescent 
protein td-Tomato.   
To ensure that the resistant clones generated were not simply more 
proliferative, we compared in vitro and in vivo proliferation of B16/3I-F4 (Resistant) 
and B16/BL6 (Parental). Using IncuCyteTM confluency assay (Fig. 2.1C) we found 
no significant difference in proliferation between the parental and resistant tumor 
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cells. We also compared in vivo tumor growth and survival of mice with parental 
and resistant tumors in both normal C57/BL6 (WT) and B6.Rag-/- mice.  Parental 
and resistant tumors without immunotherapy showed no significant difference in 
tumor growth kinetics and survival in both WT (Fig. 2.1D & Fig. 2.1A) and B6.Rag-
/- mice (Fig. 2.1E & Fig. 2.1B). In the presence of immunotherapy, however, WT 
mice with parental tumors showed reduced tumor growth and significant survival 
benefit (Fig. 2.1D). In B6.Rag-/- mice, however, both parental and resistant line 
grew at the same rate even in the presence of triple checkpoint blockade 
demonstrating that resistance depends on adaptive immunity and is not due to 
enhanced cell proliferation.  
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 Figure 2.1 
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Figure 2.1: Generation and characterization of checkpoint blockade 
immunotherapy resistant tumor cells through serial in vivo passage. (A)  
Experimental model for evolution of immunotherapy resistant B16 cell line. Tumor 
cells were harvested and cultured from non-responder mice and tumor cell lines 
were generated. Through serial in vivo passage the immunotherapy resistant cell 
line (3I-F4) was generated. (B) A bar graph shows percentage of mice who did not 
respond to immunotherapy after each in vivo passage. Data labels on the bars 
indicate name and number of tumor cells implanted for the respective passages. 
(C) The in vitro growth kinetics of the resistant tumor cell line compared to parental 
tumor cell line were determined using the IncuCyteTM confluency assay. (D) 
Survival of mice challenged with 2.5x104 parental or resistant tumor cells with and 
without immunotherapy treatment in (D) wild type and (E) Rag-/- mice.  Statistical 
significance was calculated using a Student’s T test. ns, not significant; *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. 
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2.4.2: Immunotherapy resistant tumors enriched genetic changes to evade 
immune response   
We next sought to identify the acquired genetic changes within resistant 
tumors which drove the evolution of their resistance to the resistance to 
immunotherapy phenotype. We harvested resistant 3I-F4 tumors and separated 
the tumor cells away from non-tumor  flow sorted to separate tumor cells from non-
tumor cells (hereafter referred to as microenvironment) using Fluorescence 
activated cell sorting (FACS)  for independent gene expression profiling on both 
populations (Fig. 2.2A). We observed substantial genetic diversity of expression 
when comparing gene arrays between resistant and parental tumor cells, however, 
top candidate genes generally clustered in metabolic pathways in particular, 
glycolysis, oxidative phosphorylation, oxidative stress, and hypoxia (Fig. 2.2B & 
2.2C).  
To identify pathways that were either enriched or underrepresented in 3I-
F4 tumors, we performed gene set enrichment analysis (GSEA) on both resistant 
tumor cell and microenvironmental data sets. Independent analysis of tumor cell 
and associated microenvironment gene expression gave us the unique capacity to 
investigate cross-communication between tumors cells and the surrounding 
stroma. It also gave us an opportunity to investigate the effects of these genetic 
adaptations by resistant tumor cells on anti-tumor immunity in the TME. The gene 
set ‘MANALO_HYPOXIA_DN’, representing genes that are down-regulated in 
response to both hypoxia and overexpression of an active form of HIF1A, was 
positively enriched in resistant tumor cells (Fig. 2.2E) implying an adaptation to the 
hypoxic state. Surprisingly, the same gene set was negatively enriched in resistant 
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tumors’ microenvironments, which implies that tumor cells are adapting to a state 
of hypoxia and surrounding stroma is poorly equipped to handle the hypoxic stress 
(Fig. 2.2D & 2.2E). The gene set ‘NFE2L2.V2’, representing genes up-regulated in 
embryonic fibroblasts (MEF) after knock out of NFE2L2 (Nrf2) which drives 
response to oxidative and other stresses, was positively enriched in resistant 
tumors. This suggests that resistant tumor cells have better adapted to the cellular 
stress caused by aberrant metabolism within TME (Fig. 2.2D & 2.2E). A Gene Set 
Enrichment Analysis (GSEA) and an Ingenuity Pathway Analysis (IPA) also 
revealed other metabolic crosstalk between resistant 3I-F4 tumors and their 
microenvironment.  The tumors resistant to immunotherapy showed increases in 
biological pathways involving mitochondrial oxidative phosphorylation, 
oxidoreductase, hypoxia response genes, and glycolysis. They also showed 
decreases in oxidative damage pathways, implying that these cells have adapted 
to the hypoxic environment. On the other hand, the tumor microenvironment 
showed enrichment of several hypoxia related gene sets. This implies that while 
3I-F4 tumors successfully adapt to the hypoxic state, the microenvironment is 
unable to do so due to upregulation of the gene set normally downregulated during 
a successful hypoxic adaptation.  As a consequence, the microenvironment 
suppressed anti-tumor immune function, which is reflected by the negative 
enrichments of gene sets involving T cell effector functions, myeloid (DC and 
microphages) cell activation and DC maturation (Fig. 2.2D And Supplemental Fig. 
2.2). Taken together the data suggests that resistant tumors deplete nutrients in 
the TME and create state of hypoxia in which only metabolically adapted cancer 
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cells can thrive.  Lack of glucose and environmental hypoxia thus hamper 
antitumor immunity. 
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Figure 2.2 
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Figure 2.2 Gene expression profiling and immunogenomics of 
immunotherapy resistant tumor cells 
(A) Experimental schematics of the gene expression microarray. Resistant tumors 
and control parental tumors were FACS sorted in to td-tomato positive tumor cells 
and td-tomato negative microenvironment. Both the populations were treated 
separately for microarray analysis. (B) The heat map represents fold expression 
change of highly upregulated and downregulated genes representing metabolic 
pathways. (C) A volcano plot representing log fold change in gene expression in 
immunotherapy resistant tumor cells compared to immunotherapy sensitive 
parental tumor cells.  (D) Representative GSEA plots from tumors (hypoxia and 
oxidative stress gene sets) and microenvironment (hypoxia and CD8 Teff gene 
sets). (E) Positively enriched curated (C2 MsigDB|GSEA) and GO (C5 
MsigDB|GSEA) in immunotherapy resistant tumors cells compared to 
immunotherapy sensitive parental tumor cells. (F) Negatively enriched curated (C2 
MsigDB|GSEA) and GO (C5 MsigDB|GSEA) in immunotherapy resistant tumors 
microenvironment compared to immunotherapy sensitive parental tumor 
microenvironment. 
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2.4.3: Resistant melanoma cells acquire a hypermetabolic phenotype to 
evade checkpoint blockade-mediated immunotherapeutic pressure.  
To experimentally validate the metabolic adaptations of resistant tumors, 
we assessed their glycolytic metabolism by measuring the extracellular 
acidification rate (ECAR, a readout of glycolysis), and their rate of oxidative 
phosphorylation by measuring their oxygen consumption rate (OCR, read out of 
mitochondrial respiration). The immunotherapy resistant cell line, 3I-F4, had higher 
basal levels of both ECAR and OCAR (Fig. 2.3A & 2.3B) than the parental cell line. 
The maximum glycolytic capacity and mitochondrial respiration were also elevated 
in resistant cells compared to parental cells (Fig. 2.3A & 2.3B). Interestingly, this 
enhancement of both glycolysis and oxidative phosphorylation is a departure from 
the expected Warburg effect, in which tumor cells rely primarily on glycolysis for 
ATP production even in oxygen-depleted environments. In order to further validate 
the hypermetabolic phenotype of immunotherapy resistant tumor cells, we 
analyzed their cellular metabolites using nuclear magnetic spectroscopy. The 
resistant 3I-F4 cell line showed relative increases in lactate and other TCA cycle 
metabolites (Supplemental Fig. 3.3A). We also compared metabolites extracted 
from whole tumor lysates of resistant tumors to parental tumors with and without 
treatment. Consistent with the cell line data, ex vivo resistant tumors also showed 
increased relative levels of lactate and other TCA cycle metabolites under both 
untreated and treated conditions. (Fig. 2.3C).  Interestingly, the observed increase 
in these metabolites was more profound in the presence of immunotherapy 
treatment, which suggests that treatment itself directly or indirectly triggers these 
metabolic changes in resistant tumors (Fig. 2.3C).  
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One of the major goals in the field of checkpoint blockade immunotherapy 
field is to define pre-treatment biomarkers that can predict response to therapy. In 
a previous study, increased serum LDH levels was negatively correlated with 
overall survival and progression-free survival in melanoma patients on anti CTLA-
4 treatment (181,182), and tumors are known to be primary source of lactate in 
cancer patients’ serum. Based on our in vitro and ex-vivo metabolic analyses, we 
hypothesized that the increase in lactate production in resistant tumors could serve 
as a marker to separate immunotherapy sensitive and resistant tumors by 
visualizing conversion of hyperpolarized pyruvate into lactate utilizing noninvasive 
MRI imaging. Using this approach, we showed that the rate of pyruvate to lactate 
conversion was significantly higher in immunotherapy resistant tumors (Fig. 2.3D 
& 2.3E).The in vitro, ex vivo and in vivo data suggest that checkpoint blockade 
immunotherapy resistant tumors acquire a hypermetabolic state where they 
upregulate both glycolysis and oxidative phosphorylation to evade the host 
immune response. 
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Figure 2.3 
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Figure 2.3: Resistant melanoma cells acquired hypermetabolic phenotype to 
evade checkpoint blockade mediated immunotherapeutic pressure. 
Immunotherapy resistant 3I-F4 and immunotherapy sensitive parental cells were 
analyzed using seahorse flux assay. (A) Extra cellular acidification rate (ECAR), a 
surrogate read out for glycolysis, using glycostress assay and (B) oxygen 
consumption rate (OCR), a surrogate read out for mitochondrial respiration, using 
mitostress assay were determined. (C) Heat map depicting relative changes in 
metabolites’ intensities from resistant to parental tumors in the presence and the 
absence of treatment. Tumors from mice with and without immunotherapy 
treatments were collected on day 12-16 post implantation and flash frozen on liquid 
nitrogen. The metabolites were extracted and analyzed on Avance Bruker 
spectrometer NMR. The intensities of metabolites were taken with respect to NMR 
reference compound. Heat map was then generated using Z score, which is 
relative intensities of extracted metabolites from resistant tumor lysates compared 
to parental tumor lysates. (D) A metabolic signature of resistant tumors were 
visualized using noninvasive MRI technique. Hyper polarized pyruvate were 
injected in tumor bearing mice which were then analyzed using magnetic 
resonance imaging (MRI) for pyruvate to lactate conversion ratio. (E) Normalized 
lactate to pyruvate ratio was calculated [nLAC= (Lactate +Pyruvate)/Lactate)] and 
used as a surrogate read out of glycolysis rate in resistant tumor compare to 
parental tumors. Statistical significance was calculated using a Student’s T test. 
ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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2.4.4: Resistant melanoma tumors adapt to thrive in hostile hypoxic 
conditions.  
We further investigated the role of hypoxia in mediating resistance to 
checkpoint blockade immunotherapy based on our GSEA and metabolic profile of 
resistant tumors. We used confocal microscopy to observe how resistant and 
parental tumors interact with hypoxic zones in the TME, using the Hypoxyprobe 
(hypoxia-specific reactive reagent Pimonidazole and anti- Pimonidazole staining 
antibodies) to image tumor hypoxia and td-Tomato fluorescent protein to 
discriminate tumor cells. There was no significant difference in the size of hypoxic 
regions in untreated resistant and parental tumors (Fig. 2.4A, Supplemental Fig. 
2.3B); however, in response to treatment, resistant tumors exhibited more hypoxia 
compared to parental. In addition, td-Tomato positive cancer cells in resistant 
tumors were present at a higher density within hypoxic regions than their parental 
counterpart, which is consistent with our gene expression data showing that cancer 
cells in resistant tumors have adapted to an unfavorable hypoxic conditions (Fig. 
2.4A, 2.4B and Supplemental Fig. 3B). An in vitro survival assay of resistant and 
parental tumors in a hypoxic chamber showed an increased growth kinetic for the 
resistant 3I-F4 cell line compared to parental (Fig. 2.4C) further illustrate that these 
cells can thrive under adverse metabolic conditions. Thus, checkpoint blockade 
immunotherapy-resistant 3I-F4 cells have acquired a hypermetabolic phenotype 
and created a hostile microenvironment in which they have genetically adapted to 
flourish.   
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Figure 2.4 
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Figure 2.4: Resistant melanoma tumors adapt to survive under hostile 
hypoxic conditions. (A) Resistant and parental tumors were implanted in mice 
and treated on days 3, 6, and 9. Tumors were collected on day 12-14 for confocal 
microscopy. Hypoxia (green) was imaged using Hypoxyprobe and tumor cells (red) 
were visualized based on td-Tomato expression. (B) Cell survival assay (MTS) 
performed on resistant and parental tumors in a hypoxia chamber (1% oxygen). 
Statistical significance was calculated using the Student’s t test. ns, not significant; 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
2.4.5: The nutrient-depleted microenvironment of resistant tumors creates 
unfavorable conditions for anti-tumor immune cells to function 
Next, we wanted to investigate the effects of metabolic adaptation by 
resistant tumor cells on the composition and phenotype of immune cells in the 
tumor microenvironment. We performed multicolor flow cytometry analysis to study 
tumor immune infiltrates and found that checkpoint blockade-resistant tumors 
showed significantly increased CD8 T cell infiltration in response to treatment, 
which was similar to the response seen in immunotherapy-sensitive parental 
tumors (Supplemental Fig. 2.4A). However, there was a significantly higher CD8 T 
cell density (CD8 T cell count per mg tumor mass) in parental tumors compared to 
immunotherapy resistant tumors (Fig. 2.5A) when treated with triple checkpoint 
therapy. CD8 T cells in resistant tumors vs. parental tumors showed a significant 
decrease in cell proliferation as measured by Ki-67 expression under untreated 
conditions. In response to treatment, however, there was no difference in CD8 T 
cell proliferation between parental and resistant tumors (Fig. 2.5B). CD8 T cells 
from resistant tumors exhibited decreases in expression of the T cell cytotoxicity 
marker granzyme B (Fig. 2.5C), and of Glut-1, a marker for glycolytic function, (Fig. 
2.5D),  however, there was no significant difference in expression of activation 
markers such as CTLA-4, PD-1, and PD-L1 or of the cytolytic cytokine perforin or 
of LAP, which is a surrogate marker for a suppressive cytokine tumor growth 
factor-β (TGF-β) (Supplemental Fig. 2.4B-F).   
Effector function of cytotoxic CD8 T cells are dependent on their metabolic 
fitness, in particular, their glycolytic capacity. In order to test the effect of metabolic 
adaptation of resistant tumors on cytotoxic CD8 T cell function, we measured 
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glucose uptake using fluorescently labeled glucose (2NDGB) and mitochondrial 
membrane potential using MitoTracker Deep Red FM in tumor infiltrating T cells. 
CD8 T cells demonstrate reduced glucose uptake and showed high Mito FM 
staining in resistant tumors compared to parental tumors (Fig. 2.4 E). These data 
suggest that checkpoint blockade immunotherapy enhances cytotoxic CD8 T cell 
infiltration into resistant tumors, but their density and intra-tumor effector functions 
are compromised in the TME of resistant vs. parental B16 melanoma.  
Compared to parental tumors we did not observed a significant difference 
in infiltration (Supplemental Fig. 5A) or proliferation (Supplemental Fig. 5A) of CD4 
T effector cells in resistant tumors with and without therapy. We did not observe 
any significant difference in the expression of CTLA-4, PD-1, Glut-1 and LAP by 
CD4 T effector cells from parental and resistant tumors (Supplemental Fig. 2.5B-
F). These data imply that the TME of resistant tumors may not affect CD4 T cells 
as adversely as it does CD8 T cells.  
We also investigated the effects of metabolic adaptation of tumor cells on 
the tumor-supportive elements of the immune microenvironment, especially on T 
regulatory cells (Treg) and Myeloid Derived Suppressor cells (MDSC). There was 
no significant difference in either Treg infiltration or CD8:Treg ratio in resistant 
tumors in comparison to parental tumors, with and without therapy (Fig. 2.6A & 
2.6B). We also did not observe any significant difference in proliferation of 
regulatory T cells in resistant tumors, as depicted by Ki67 staining (Fig. 2.6C). In 
resistant tumors, however,  regulatory T cells significantly increased CTLA-4 
expression (Fig. 2.6D) in response to therapy, which can participate in inhibiting T 
cell activation (183). Similarly, there was no significant difference in MDSC 
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infiltration and CD8: MDSC ratio in resistant tumors compared to parental tumors, 
however, in resistant tumors MDSC exhibited signs of enhanced-suppressive 
capacity. The expression of suppressive enzymes IDO and arginase was 
significantly increased in MDSCs from resistant tumors in response to treatment.  
Together, these data suggest that metabolic adaptation of immunotherapy 
resistant tumors creates a hostile microenvironment where antitumor CD8 T cells 
display decreased effector function and tumor-supportive populations such as 
Tregs and MDSCs become more suppressive.  
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Figure 2.5 
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Figure 2.5: Effects of metabolic adaptation by resistant tumors on cytotoxic 
T cell infiltration and function. (A) T cell density per tumor weight was 
determined using flow cytometry analysis.  Resistant and parental tumors were 
implanted in mice and treated on days 3, 6 and 9. Tumors were weighed before 
harvesting for flow cytometric analysis. Data are expressed as the total number of 
CD8 positive cells per milligram of tumor. (B) T cell proliferation analysis using 
multicolor flow cytometry. The data was presented as mean fluorescence intensity 
of Ki-67, a T cell proliferation marker.  T cell function was analyzed using multicolor 
flow cytometry analysis. The data presented as mean fluorescence intensity of (C) 
Granzyme B and (D) Glut 1 receptor, T cell function and activation markers. (E) 
Analysis of glycolysis and oxidative phosphorylation on tumor infiltrating CD8 T 
cells. Resistant and parental tumors were implanted in mice and treated on day 3, 
6 and 9. The tumors were harvested for flow cytometry analysis and stained with 
Mitored and other phenotypic markers.  The mice were intravenously injected with 
fluorescently labeled glucose (NBDG) thirty minutes before they were sacrificed 
for the tumor harvest.  The data is presented as mean fluorescent intensity of 
NBDG, and Mitored on tumor infiltrating CD8 T cells, splenic CD8 T cells and td-
Tomato positive tumor cells.  Statistical significance was calculated using the 
Student’s t test. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001. 
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Figure 2.6 
 
69 
 
 
 
Figure 2.6: Effects of metabolic adaptation by resistant tumors on infiltration 
and function of Treg and MDSC. (A) Regulatory T cells as a percentage of total 
tumor infiltrating T cells. Resistant and parental tumors were implanted in mice and 
treated on days 3, 6 and 9. The tumors were harvested on day 12 for multicolor 
flow cytometry analysis. Regulatory T cells (Treg) were gated on CD4 positive and 
Foxp3 positive populations.  (B) CD8/Treg ratios within the tumor were calculated 
by dividing the number of CD8+CD3+ cells by the number of CD4+Foxp3+ cells.  
Proliferation and function of tumor infiltrating T regulatory cells were performed 
using multicolor flow cytometry. (C) Treg proliferation data was presented as mean 
fluorescent intensity of Ki-67, a proliferation marker.  (D)  Expression of CTLA-4 
on tumor infiltrating Treg. The data is presented as mean fluorescence intensity of 
CTLA-4 by T regulatory cells. (E) Myeloid Derived Suppressor Cells (MDSC) as a 
percentage of total tumor infiltrating CD45+CD3- cells. MDSC were gated on 
CD11b+ and Gr1+ double positive populations.  (F) CD8/MDSC ratios within the 
tumor were calculated by dividing the number of CD8+CD3+ cells by the number 
of CD11b+Gr1+ cells.  The suppressive function of tumor MDSCs were analyzed 
using multicolor flow cytometric analysis and data is presented as mean 
fluorescent intensity of (G) Indoleamine-pyrrole 2,3-dioxygenase (IDO) and (H) 
Arginase. Data were pooled from ≥ 2 experiments with 5 mice per group.  Bars 
represent mean ± SD.  Statistical significance was calculated using the Student’s 
t test. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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2.4.6: Monogenic overexpression of PGAM2 and ADH7 in parental tumors 
confers resistance to checkpoint blockade immunotherapy  
We next sought to validate the monogenic effect of candidate metabolic 
genes associated with acquisition of checkpoint blockade resistance identified by 
gene expression profiling of 3I-F4. We overexpressed PGAM2 (top hit in 
expression analysis; involved in glycolysis) and ADH7 (one of the top hits; gene 
involved in oxidoreductase pathway which decreases oxidative stress by reducing 
NAD to NADH) in parental cells (B16/BL6-td). We then implanted tumor cells 
overexpressing either PGAM2, ADH7 or empty vector in mice to monitor tumor 
growth and survival with or without checkpoint blockade immunotherapy. When 
mice were not treated with checkpoint blockade immunotherapy, PGAM2 and 
ADH7 overexpressing tumors did not show significant differences in tumor growth 
or survival (Fig. 6A & B).  When treated with checkpoint blockade immunotherapy, 
however, PGAM2 and ADH7 overexpressing tumors became resistant to therapy 
(Fig. 6A & C), thus implies a role for PGAM2 and ADH7 genes in mediating 
metabolic changes in 3I-F4 tumors that contribute to the immunotherapy 
resistance phenotype.   
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Figure 2.7 
 
Figure 2.7: Monogenic validation of candidate genes PGAM2 and ADH7.  
PGAM2 was overexpressed in the parental tumor cell line B16/BL6-td using a 
retroviral vector (A) Survival curve and (B) tumor growth were monitored in mice 
challenged with tumor cells overexpressing PGAM2 and empty vector (control) 
with and without immunotherapy treatment. ADH7 was overexpressed in the 
parental tumor cell line B16/BL6-td using a retroviral vector and survival curve (C) 
and (D) tumor growth were monitored in mice challenged with tumor cells 
overexpressing ADH7 and empty vector (control) with and without immunotherapy 
treatment.  Statistical significance was calculated using the Student’s t test. ns, not 
significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000. 
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2.4.7: Melanoma patient tumors which fail to respond to immunotherapy 
show enhanced expression of metabolic pathways resembling 3I-F4  
We sought to validate the role of metabolic adaptation in modulating the 
response to checkpoint immunotherapy in human patient samples. To do so, we 
performed gene expression analysis on mRNA samples from a patient cohort (173) 
consisting of metastatic melanoma patients who progressed on CTLA-4 blockade 
and then were treated with αPD-1. Patients were biopsied prior to αPD-1 therapy 
and responses were assessed with serial CT scan after initiation of therapy. As 
defined earlier (173), responders were defined by absence, stable or reduced 
tumor size on CT scan, and non-responders were defined by an increased tumor 
size or tumor control less than 6 months. There were four patients who responded 
and five who did not respond to therapy. GSEA and IPA analysis showed that 
compared to responders, non-responders enriched similar metabolic pathways to 
those identified in our resistant mouse models.  Non-responders also showed 
alteration in gene expression focused on similar nodes in the glycolysis and 
oxidative phosphorylation pathways compared to resistant tumor models (Fig. 
2.8C). These findings suggest that the murine model we generated to study 
checkpoint immunotherapy resistance has human relevance (Fig. 2.8B & 2.8C).   
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Figure 2.8 
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Figure 2.7: Validation of immunotherapy resistant genetic signature in 
human melanoma. (A) Metastatic melanoma patients were treated with anti-
CTLA-4 and non-responders were biopsied and then treated with anti-PD-1. 
Patients were then evaluated for clinical benefit. Gene expression analyses was 
performed on 4 responders and 5 non responders. (B) Enrichment of metabolic 
pathways in patients who did not respond to therapy. Bioinformatics analysis was 
performed using GSEA and IPA analysis. (C) The glycolysis pathway was 
generated using IPA showing relative expression of genes in patients who did not 
respond to therapy compared to the responders. The red color indicates 
upregulation of a gene, while the green color indicates its downregulation in 
patients who did not respond to therapy compared to responders.  (C) Similarly, 
the glycolysis pathway was generated in immunotherapy resistant mouse tumors 
showing relative expression of genes in comparison to immunotherapy-sensitive 
parental mouse tumors.  
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2.4.8: Nonspecific therapeutic modulation of tumor metabolism could 
negatively affect anti-tumor immunity  
Based on our in silico and experimental findings, we hypothesized that 
therapeutically reversing the metabolic adaptation of tumor cells would make them 
sensitive to checkpoint blockade immunotherapy. Since, resistant tumors showed 
increases in both glycolysis and oxidative phosphorylation, we treated resistant 
tumors and control parental tumors with 2-Deoxy-D-glucose (2DG), a structural 
analogue of glucose that inhibits glycolysis, an LDHA inhibitor (GSK2837808A), a 
selective lactate dehydrogenase A inhibitor (58,184,185), and an oxphos inhibitor 
(IACS-10759) (186) which is a mitochondrial complex I inhibitor that blocks 
oxidative phosphorylation (Fig. 2.9A & 2.9B). Unexpectedly, all three drugs failed 
to provide any therapeutic advantage to resistant tumors when given in 
combination with immunotherapy. In the presence of 2DG and the Oxphos inhibitor 
(IACS-10759), even immunotherapy sensitive parental tumors lost therapeutic 
benefit in response to checkpoint blockade immunotherapy (Fig. 2.9A & 2.9B). 
Metformin (57) and TH-302(56) reduce hypoxia and are known to synergize when 
combined with immunotherapy. Because resistant tumors metabolically adapt to 
flourish in hypoxic conditions, we hypothesized that ablating hypoxia would break 
the immune tolerance created by resistant tumors.  Contrary to our expectations, 
neither TH-302 nor Metformin was able to sensitize resistant tumors to checkpoint 
blockade immunotherapy (Fig. 2.9A & 2.9B).  
We also tested if repolarizing the more suppressive tumor immune 
microenvironment by combining immunotherapy with STING agonist (c-di-GMP) 
(124), PI3Kγ inhibitor (IPI549) (120) or STAT3 ASO (AZD9150) (187) would break 
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immune tolerance. However, these strategies also failed to sensitize resistant 3I-
F4 tumors to checkpoint blockade (Fig. 2.9A & 2.9C). We also sought to break the 
metabolic anergy of cytotoxic CD8 T cells induced by resistant tumors by treating 
with TNF receptor superfamily agonist antibodies in combination with checkpoint 
blockade immunotherapy (188,189). When we treated resistant tumors with 
agonist antibodies against 4-1BB or CD40 (Fig. 2.9A & 2.9D), however, we did not 
see any added therapeutic benefit (188,189).  While evolving the immunotherapy 
resistant clones, we made a visual observation that tumors increased vasculature 
with every increasing passage (Supplemental Fig. 2.6A & 2.6B). In our model, we 
did not see any increase in therapy mediated antitumor immune response when 
combined with αVEGFRII, an antiangiogenic therapy (Fig. 2.9A & 2.9D) (110). 
Together, metabolic modulators (2DG, GSK2837808A, and IACS-10759), hypoxia 
ablating agents (TH302 and Metformin), agents targeting suppressive tumor 
immune cells (STING agonist, IPI549, and  STAT3 ASO), TNF super family agonist 
antibodies (α4-1BB and αCD40) and antiangiogenic therapy (αVEGF) could not 
reverse the therapy resistance established by  checkpoint blockade –resistant 3I-
F4 tumors.  
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Figure 2.9 
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Figure 2.9: Therapeutic modulation of tumor metabolism fail to reverse 
immunotherapy resistance. (A) Experimental design and treatment strategies for 
tumor survival experiments.  Wild type mice on day 0 were challenged with therapy 
resistant tumors and control parental tumors. Mice were then treated with FVAX 
plus αCTLA-4, αPD-1 and αPD-L1 on days 3, 6 and 9 in combination with various 
therapeutic agents or control vehicle as described in the Methods section. (B) 
Survival graph of resistant tumors treated with metabolic modulators and hypoxia 
targeting drugs (glucose analogue-2DG, Lactate dehydrogenase Inhibitor- 
GSK2837808A, Oxidative phosphorylation inhibitor-IACS-10759, Metformin given 
intraperitoneally, Metformin in drinking water, and hypoxia activated prodrug-
TH302). (C) Survival graph of mice treated with therapeutic agents targeting the 
suppressive tumor microenvironment (STING agonist, PI3 Kinase inhibitor-IPI549, 
and STAT3 ASO-AZD9150. (D) Survival graph of resistant tumors treated with 
TNF superfamily agonist antibodies, α41BB and α-CD40, and antiangiogenic 
antibodies, α-VEGFRII.   
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2.5: Discussion  
To our knowledge, we are the first to generate an immunotherapy resistant 
clone of B16 melanoma to conduct an unbiased investigation of acquired 
resistance to checkpoint blockade immunotherapy and apply the knowledge to 
predict treatment outcomes using noninvasive methods.  The immunotherapy- 
resistant murine melanoma tumor increased glycolysis, oxidoreductase, and 
oxidative phosphorylation, which contributed to T cell dysfunction in the 
microenvironment and conferred resistance to checkpoint blockade 
immunotherapy.  
 Tumors resistant to immunotherapy defied Warburg theory, which states 
that tumor cells rely on glycolysis alone for generation of ATP and downregulate 
mitochondrial oxidative phosphorylation. Resistant 3I-F4 tumors showed an 
increase in both glycolysis and oxidative phosphorylation, which we define as a 
hypermetabolic state. Phosphoglycerate mutase 2 (PGAM2), a glycolytic enzyme, 
was found highly upregulated in immunotherapy resistant tumor cells compared to 
parental cells. PGAM2 converts 2-phosphoglycerate to 3-phosphoglycerate, which 
is an important step in glycolysis as well as anabolism (biosynthesis) of amino 
acids and nucleotides (190). The phosphoglycerate mutase family (PGAM) is also 
involved in mediating response to oxidative stress through SIRT2 binding, and 
protecting cells from oxidative damage by regulating NADPH homeostasis (190).  
The overactive glycolysis pathway in resistant tumor cells can induce oxidative 
stress, which may be counterbalanced by upregulation of oxidoreductase 
pathways. Alcohol dehydrogenase-7 (ADH7), a gene in the oxidoreductase family, 
is an NAD(P)+/NAD(P)H coupling agent (191,192). We believe that highly 
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upregulated ADH7 in resistant tumor cells offers several advantages to highly 
glycolytic resistant tumors (191,192). It reduces oxidative stress, generates 
reduced glutathione (GSH), a known scavenger of reactive oxygen species, and 
NAD(P)H, a substrate in mitochondrial oxidative phosphorylation (191,192). We 
propose that upregulation of these glycolytic nodes and oxidoreductase pathways 
provide metabolic advantages to tumor cells, allowing them to increase 
mitochondrial oxidative phosphorylation and create a state of hypoxia. The 
increase in oxidoreductase pathways also aides the tumor cells in adapting to and 
flourishing in hostile hypoxic conditions where antitumor immune cells are 
rendered inert.     
Immunotherapy resistant tumors did not show substantial declines in the 
percentage of CD8 T cell infiltration, rather they increased the percentage of 
infiltrating CD8 T cells in response to therapy (193). These findings corroborate a 
previously reported study in which an increase in CD8 T cell infiltration in response 
to CTLA-4 and PD-1 blockade therapy was observed in a cohort of non-responder 
melanoma patients (174).  In parental tumors, however, CD8 T cell density (CD8 
T cell numbers per tumor weight) was significantly higher compare immunotherapy 
resistant 3I-F4 tumors. Hypermetabolic resistant tumor cells can deplete nutrients 
in the tumor microenvironment, increase tumor-derived lactate and create a state 
of hypoxia. In this hostile microenvironment, cytotoxic CD8 T cells lose their 
metabolic fitness (61,62,194-196) and associated effector functions.  We have also 
seen an increase in the suppressive capacity of Treg and MDSC in resistant 
tumors, which also could be a result of low glucose levels and the presence of 
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tumor derived lactate as these conditions are known to make Treg and MDSC 
more immune suppressive (58,197).  
There are efforts in the field to expand the therapeutic benefit of checkpoint 
blockade immunotherapy by understanding the mechanisms of relapse and 
acquired resistance. Upregulation of alternative immune checkpoint pathways 
such as TIM3 (97,172) and VISTA (95) were seen in patients who relapsed after 
PD-1 therapy. In our tumor model we did not see evidence of substantial increased 
expression of alternative checkpoint pathways in both our gene signature and flow 
cytometry analysis. We did not see any changes in the genetic expression of IFNγ 
and JAK1 pathways in our resistant tumor (49,198). We did not observe 
downregulation of MHC class I or II complexes on the surface of resistant tumors 
(1,30,49). In the resistant tumor model, we rather saw an increase in both class I 
and II antigen presentation at both genetic and protein levels reflecting loss of 
environmental immune pressure.  
A critical aspect of our study was the enrichment of genetic signatures of 
immune resistance using in vivo passaging. This experimental model also allowed 
us to separate tumor cells from the surrounding tumor microenvironment and to 
perform genetic analyses separately. It gave us the advantage of understanding 
how genetic changes can be acquired in resistant tumors in response to 
immunotherapeutic pressure. We could also investigate metabolic and 
immunological cross-communication between tumor cells and their 
microenvironment.  This provide a number of advantages over analysis of whole 
tumor samples, where it is difficult to separate the biological effects of treatment 
on tumor cells from rest of the tumor microenvironment. In vivo passaging and 
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analysis of tumor cells separately from the tumor microenvironment, which were 
lacking in prior studies, facilitated both the identification of relevant genetic 
changes and a reduction in the signal-to-noise ratio. We believe that this tumor 
model could be a useful tool to screen pharmaceutical drug candidates to 
overcome checkpoint resistance. We also showed that this signature can be 
imaged in vivo using a novel MRI technique coupled with a hyperpolarized 
pyruvate probe.  This technique has just been approved for human studies, 
(199,200) and if applied in immune-oncology (I/O), might provide the first non-
invasive approach to assessing whether or not a given patient's tumor is likely to 
respond to checkpoint blockade. 
One potential limitation of our study was that the tumor model could not 
distinguish between mechanisms that drive resistance to each single 
immunotherapy since a combination of three checkpoint blockade antibodies 
(αCTLA-4, αPD-1 and αPD-L1) were used to generate immunotherapy-resistant 
clones. The metabolic adaptation of resistant tumor cells may have been the most 
prominent mechanism driving resistance, even in the presence of all three 
checkpoint blockade antibodies, and could therefore be clinically relevant to target. 
While metabolic adaptation appears prominent in our system, we cannot deny 
other biological processes may contribute to resistance to immunotherapy such as 
mutational load (49,111,173), neoantigen load (173), and copy number loss 
(112,174). These were defined in earlier studies as mechanisms driving resistance 
to PD-1 and CTLA-4 monotherapy. It would be interesting to analyze the role of 
mutational landscape in our resistant tumor model, although this was not the focus 
of the current study.  
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We therapeutically targeted metabolic adaptation of resistant tumors with 
metabolic modulators 2DG, LDH inhibitor and oxphos inhibitor but failed to reverse 
resistance to therapy. Oxphos inhibitor and 2DG, rather, worsened the survival 
benefits of immunotherapy-sensitive parental tumors. While tumor cells rely on 
glycolysis and mitochondrial oxidative phosphorylation, both metabolic pathways 
are equally important to the anti-tumor immune component as well.  Thus, we 
believe there is a metabolic tug-of-war between tumor and immune cells in the 
tumor microenvironment (68,201). Understanding the metabolic differences 
between tumor cells and the immune compartment at the molecular level would 
facilitate the design of therapeutic agents targeting tumor specific metabolism 
without affecting the immune compartment. Agents that are known to repolarize 
the immunosuppressive myeloid compartment such as STING agonists, PI3K 
Inhibitors, anti CD40 antibodies, and a STAT3 ASO failed to break immune 
tolerance in immunotherapy-resistant tumors. Anergic CD8 T cells could not be 
rescued by 4-1BB or CD40 agonist therapy either. Interestingly, therapeutic agents 
targeting hypoxia (TH302 and metformin) and angiogenesis (anti VEGFRII 
antibodies) also could not reverse the therapy resistance in immunotherapy 
resistant tumors. We hypothesize that the rapid growth kinetics characteristic of 
B16 melanoma contributes to the complete resistance of this model, and that the 
above agents might require a larger therapeutic window in order to sensitize 3I-F4 
tumors to checkpoint blockade. 
In conclusion, B16 melanoma acquired immunotherapy resistance by 
coordinated upregulation of the glycolytic, oxidoreductase pathways and 
mitochondrial oxidative phosphorylation to create a metabolically hostile 
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microenvironment in which T cell function is profoundly suppressed.  
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Supplemental Figure 2.1 
 
Supplemental Figure 2.1: Generation and characterization of checkpoint 
blockade immunotherapy resistant tumor cells through serial in vivo 
passage. (A) Tumor growth was monitored in mice challenged with parental or 
resistant tumor cells with and without immunotherapy treatment in wild type and 
(B) Rag-/- mice. 25000 resistant and parental tumor cells were implanted in wild 
type and Rag-/- mice. The tumor growth was monitored with and without treatment. 
Statistical significance was calculated using a Student’s t test. ns, not significant; 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Supplemental Figure 2.2 
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Figure Supplemental 2.2: Gene expression profiling and immunogenomics 
of the immunotherapy-resistant tumor microenvironment  (A) Volcano plot 
representing log fold change in gene expression in immunotherapy resistant tumor 
microenvironment compared to immunotherapy sensitive parental tumor 
microenvironment. (B) Positively and (C) negatively enriched immunological gene 
signature (C7 MsigDB|GSEA) in immunotherapy-resistant tumor 
microenvironment compared to immunotherapy-sensitive parental tumor 
microenvironment.  
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Supplemental Figure 2.3 
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Figure 2.3: Metabolic signature of resistant cell line using NMR profiling and 
hypoxyprobe staining of resistant tumors. (A) Heat map of relative NMR 
metabolite intensities in resistant cell line (3I-F4) compared to parental cell line 
(B16/BL-td).  Cell lines were washed with PBS twice and flash frozen on liquid 
nitrogen. The intensities of metabolites were taken with respect to NMR reference 
compounds. A heat map was then generated using Z score, which depicts relative 
intensity of metabolites in resistant cell line lysate compared to parental cell line 
lysate. (B) Resistant and parental tumors were implanted in mice (no treatment). 
Tumors were collected on day 12-14 for confocal microscopy. Hypoxia (green) was 
imaged using Hypoxyprobe and tumor cells (red) were visualized with td-Tomato 
fluorescent protein.  
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Supplemental Figure 2.4 
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Supplemental Figure 2.4: Effects of metabolic adaptation by resistant tumors 
on function of cytotoxic T cells. (A) CD8 T cell percentage of total tumor 
infiltrating T cells. Resistant and parental tumor were implanted in mice and treated 
on day 3, 6 and 9. Tumors were harvested for flow cytometric analysis. CD8 T cells 
were gated on CD3+CD8+ cells. The data presented show CD8 T cells as a 
percentage of total CD3 T cells.  T cell function was analyzed using multicolor flow 
cytometry analysis. The data are presented as mean fluorescent intensity of (B) 
perforin (C) CTLA-4, (D) PD-1, (E) LAP and (F) PD-L1. Data were pooled from ≥ 2 
experiments with 5 mice per group.  Bars represent mean ± SD. Statistical 
significance was calculated using a Student’s t test. ns, not significant; *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Supplemental Figure 2.5 
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Supplemental Figure 2.5: Effects of metabolic adaptation by resistant tumors 
on cytotoxic CD4 T effector cell infiltration and function. (A) CD4 T effector 
cells as a percentage of total tumor infiltrating CD3 T cells. Resistant and parental 
tumor were implanted in mice and treated on day 3, 6 and 9. Tumors were 
harvested for flow cytometric analysis. CD4 T effector cells were gated as CD4 
positive and Foxp3 negative. The data presented show CD4+ FoxP3- (CD4Teff) 
cells as a percentage of total CD3 T cells.  T cell proliferation and function of tumor 
infiltrating CD4 T cells were performed using multicolor flow cytometry. The CD4 
T cell proliferation data was presented as mean fluorescent intensity of Ki-67, a 
proliferation marker.  T cell function data was presented as mean fluorescent 
intensity of (C) Granzyme B, (D) Glut 1 receptor, (E) CTLA-4, and (F) PD-1, T cell 
function and activation markers. Data were pooled from ≥ 2 experiments with 5 
mice per group.  Bars represent mean ± SD. Statistical significance was calculated 
using the Student’s t test. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. 
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Supplemental Figure 2.6 
 
Supplemental Figure 2.6: Large vascular formation by resistant tumors. (A) 
Representative pictures showing neo-vascular formation by resistant tumors with 
increasing in vivo passages of generating immunotherapy resistance. (B) 
Histogram representing percentage of total mice with large, apparent vasculature. 
Total 15 mice per passage were implanted with respective immunotherapy 
resistant tumor cell line (3I-F1, 3I-F2, 3I-F3 and 3I-F4). The mice with neo-
vasculature were counted and plotted as percentage of the total number of mice 
for each passage. 
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Table 2.1: A patient cohort representing treatment, biopsy, clinical 
evaluation and gene arrays analysis. 
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Chapter 3: 4-1BB Induced Liver Inflammation 
 
 
 
Activation of 4-1BB on liver myeloid cells triggers 
hepatitis via an interleukin-27 dependent pathway 
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3.1: Abstract 
Agonist antibodies targeting the T cell co-stimulatory receptor 4-1BB 
(CD137) are among the most effective immunotherapeutic agents across pre-
clinical cancer models.  In the clinic, however, development of these agents has 
been hampered by dose-limiting liver toxicity.  Lack of knowledge of the 
mechanisms underlying this toxicity has limited the potential to separate 4-1BB 
agonist driven tumor immunity from hepatotoxicity. The capacity of 4-1BB agonist 
antibodies to induce liver toxicity was investigated in immunocompetent mice, with 
or without co-administration of checkpoint blockade, via 1) measurement of serum 
transaminase levels, 2) imaging of liver immune infiltrates, and 3) qualitative and 
quantitative assessment of liver myeloid and T cells via flow cytometry.  Knockout 
mice were used to clarify the contribution of specific cell subsets, cytokines and 
chemokines. We find that activation of 4-1BB on liver myeloid cells is essential to 
initiate hepatitis.  Once activated, these cells produce interleukin-27 that is required 
for liver toxicity.  CD8 T cells infiltrate the liver in response to this myeloid activation 
and mediate tissue damage, triggering transaminase elevation.  FoxP3+ regulatory 
T cells limit liver damage, and their removal dramatically exacerbates 4-1BB 
agonist-induced hepatitis.  Co-administration of CTLA-4 blockade ameliorates 
transaminase elevation, whereas PD-1 blockade exacerbates it.  Loss of the 
chemokine receptor CCR2 blocks 4-1BB agonist hepatitis without diminishing 
tumor-specific immunity against B16 melanoma. 4-1BB agonist antibodies trigger 
hepatitis via activation and expansion of interleukin-27-producing liver Kupffer cells 
and monocytes.  Co-administration of CTLA-4 and/or CCR2 blockade may 
minimize hepatitis, but yield equal or greater antitumor immunity. 
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3.2: Introduction 
The transformative efficacy of checkpoint blockade immunotherapy for the 
treatment of melanoma has revolutionized the field of oncology and initiated a new 
era of immune-targeted therapeutics (202,203). Beyond blockade of T cell co-
inhibitory receptors, agonist antibodies which activate tumor necrosis factor 
superfamily receptors have demonstrated significant therapeutic potential both in 
pre-clinical models and clinical trials (204).  Among these agonists, acators of the 
co-stimulatory receptor 4-1BB (CD137) have demonstrated exceptional potency 
across multiple pre-clinical tumor models, as well as the capacity to elicit objective 
clinical responses in patients with diverse cancers (205,206). 
In addition to mediating tumor regressions, releasing the “brakes” on T cell 
responses with checkpoint blockade can also trigger T cell responses targeting 
normal self-tissues known as Immune Related Adverse Events (IRAE).   These 
IRAE can be severe and even life-threatening, but are readily managed with timely 
steroid intervention (207).  4-1BB agonist antibodies, by contrast, can effectively 
treat autoimmunity in a variety of murine models and may even ameliorate CTLA-
4 antagonist antibody-induced IRAE (208,209).  Despite this, these agents induce 
a unique spectrum of on-target adverse events ranging from mild to moderate 
hematologic perturbations, up to high grade transaminitis and potentially fatal 
hepatotoxicity (210,211).   
We sought to elucidate the underlying mechanisms by which α4-1BB 
antibody therapy promotes liver damage, and to explore potential avenues to 
uncouple augmentation of anti-tumor immunity from hepatitis.  Results presented 
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here demonstrate that 4-1BB agonist induced hepatotoxicity initiates at the myeloid 
level through activation of liver-resident Kupffer cells. Moreover, we find that the 
inflammatory cytokine interleukin 27 (IL-27), released from these cells in response 
to activation, is critically required for hepatic damage.  We further show that, in 
contrast to CD40 agonist induced acute hepatotoxicity, 4-1BB agonist antibody 
therapy induces a chronic hepatotoxicity characterized by dense and persistent T 
cell infiltration in the hepatic portal zones.  This infiltrate is dominated by CD8+ T 
cells which are the primary effectors of liver tissue injury.  CD4+Foxp3+ regulatory 
T cells (Treg), on the other hand, act to maintain tissue tolerance and limit α4-1BB-
induced hepatic damage.  Treg ablation severely exacerbates 4-1BB agonist liver 
inflammation and abrogates the capacity of CTLA-4 blockade to ameliorate 
transaminitis.  Finally, we show that chemotaxis of immune cells into the liver is a 
critical step in the progression of liver injury.  While hepatogenic immune 
responses following 4-1BB agonist therapy rely heavily on the chemokine 
receptors CCR2 and, less so, to CXCR3, these receptors appear to be largely 
dispensable for anti-melanoma immunity in the same animals. These data suggest 
that differential trafficking requirements for the liver and tumor microenvironments 
may be exploited to increase the tumor selectivity of 4-1BB agonist antibody 
immunotherapy.   
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3.3: Materials and Methods 
3.3.1: Animals 
Male (6wk) C57BL/6 mice were purchased from Taconic Biosciences 
(Hudson, NY).  4-1BB-/-, EBI3-/-, IL27 receptor alpha-/-, β2M-/-, MHCII-/-, Foxp3-DTR, 
CXCR3-/-, CCR2-/-, and CCR5-/- mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME). All procedures were conducted in accordance with the 
guidelines established by the U.T. MD Anderson Cancer Center Institutional 
Animal Care and Use Committee. 
3.3.2: Cell lines and reagents 
B16 melanoma, B16-Flt3-ligand (FVAX) and B16-Ova were 
obtained/created and cultured as described (94,180). The BV421-labeled H2-Kb 
epitope OVA257-264 (SIINFEKL)-containing tetramer was acquired from the 
Tetramer Core Facility at the National Institute of Health (Emory University, Atlanta 
GA).  
3.3.3: Therapeutic antibodies 
T cell co-stimulatory modulating antibodies were purchased from BioXcell: 
4-1BB (3H3 [Rat IgG2a], 250 μg/dose), CTLA-4 (9D9 [mouse IgG2b] or 9H10 
[Syrian Hamster Ig], 100 μg/dose), PD-1 (RMP1-14 [Rat IgG2a], 250 μg/dose), and 
CD40 (FGK4.5 [Rat IgG2a], 100 ug/dose). All doses indicate quantity administered 
per injection.  The mouse CTLA-4 antibody 9D9 engages the mouse IgG2b 
receptor which gives it a low to moderate ADCC capacity similar to the human 
CTLA-4 antibody ipilimumab (human IgG1).  The mouse 4-1BB antibody 3H3 is 
more similar to the human antibody urelumab as it exhibits strong agonist activity, 
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while utomilumab is a weaker agonist.  RMP-14 is a purely blocking antibody for 
PD-1 with weak Fc receptor binding similar to the human PD-1 antibodies 
pembrolizumab and nivolumab which are human IgG4.  
3.3.4: Immune ablation and reconstitution 
C57BL/6 mice or 4-1BB-/- mice were sub-lethally irradiated  (500 rads) using 
a Cesium-137 irradiator. One day later, splenic lymphocytes were isolated using 
CD90.2 magnetic beads (Miltenyi Biotec, San Diego, CA) and injected i.v. at 2X106 
cells/mouse into irradiated hosts.   
3.3.5: Antibody treatment and liver enzyme analysis  
Antibodies were given i.p. for 3 doses every 3 days.  On day 16 after 
initiation of therapy mice were bled and serum levels of aspartate transaminase 
(AST), alanine transaminase (ALT), and alkaline phosphatase (AP) were 
measured by the MDACC Veterinary Diagnostic Laboratory.  Mice were sacrificed, 
livers were perfused with PBS and harvested for immune infiltrates.     
3.3.6: Tumor therapy 
Wild type, CCR2-/-, CXCR3-/-, or CCR5-/- mice were implanted s.c. with 
3X105 B16-Ova cells on the flank as described (94,180).  On days 3,6, and 9 mice 
received α4-1BB i.p, and a mixture of irradiated FVAX and B16-Ova s.c. on the 
opposite flank as described (94).  On day 19, mice were sacrificed and tumors and 
perfused livers were harvested for analysis of immune infiltrates. 
3.3.7: Treg depletion and adoptive transfer 
Mice bearing the diphtheria toxin (DT) receptor driven by the Foxp3 
promoter (Foxp3-DTR) were administered DT at 10 μg/kg one day prior to α4-1BB 
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and every 3 days thereafter until sacrifice. Alternately, CD4+CD25+CD3+ cells were 
FACS sorted from naïve spleens and 5X105 cells were injected into host mice one 
day prior to immunotherapy.  
Myeloid cells were adoptively transferred by magnetically sorting bone 
marrow-derived monocytes using a monocyte isolation kit (Miltenyi Biotec, Auburn 
CA).  Sorted cells (CD45.2) were adoptively transferred at 2X106 cells/mouse into 
congenically marked (CD45.1) mice before initiation of therapy.     
3.3.8: Cell isolation 
Livers were perfused with PBS and tumors were harvested for analysis of 
immune infiltrate as described (212,213).   
3.3.9: Flow cytometry analysis 
Samples were fixed using the Foxp3/Transcription Factor Staining Buffer 
Set (Thermo) and then stained with up to 16 antibodies at a time from Biolegend, 
BD Biosciences, and Thermo.  Flow cytometry data was collected on an 18-color 
BD LSR II cytometer and analyzed in FlowJo (Treestar). 
3.3.10: Immunohistochemistry  
Each liver lobe was collected and formalin fixed separately for ≥ 24 hours. 
Tissues were then paraffin embedded (FFPE), sectioned and stained for H&E and 
IHC for CD8 and F4/80, at the MDACC Research Histology, Pathology, and 
Imaging Core at Science Park.  
Two sections were generated from the left lateral lobe at the widest 
dimension, and stained by H&E. H&E sections were evaluated by semi-
quantitative scoring based on the number of inflammatory and necrotic cells in the 
104 
 
 
 
portal triad, central vein, or parenchyma. A score of 0 or nil indicates no 
inflammation; Score 1, minimal inflammation, <15 inflammatory cells around portal 
triad, central vein, or in parenchyma; Score 2, mild inflammation, > 15 inflammatory 
cells around portal triad, central vein, or in parenchyma; Score 3: moderate 
inflammation, > 30, inflammatory cells around portal triad, central vein, or in 
parenchyma, and Score 4: severe inflammation, approximately > 50 cells around 
portal triad, central vein, or in parenchyma.  
Two sections per animal per group were stained with the following 
immunohistochemical stains: CD8 and F4/80. The number of CD8+ and F4/80+ 
cells in the liver, both at the perivascular zones (central vein or portal area) and in 
the parenchyma, were counted separately in a microscopic field at 20X 
magnification. Four areas with the most abundant infiltration were selected for both 
areas and the average number per animal was calculated as described in Peng 
et.al. 2015(214). 
3.2.11: Immunofluorescence staining and imaging 
Tissues were collected and flash frozen in liquid nitrogen. The frozen 
tissues were embedded in Tissue-Tek® OCT Compound (Sakura, Torrance, CA) 
and sectioned at the MD Anderson Histology Core. The sectioned tissues were 
fixed with acetone for 10 minutes, then stained with various antibodies and 
mounted in Prolong Gold (Invitrogen, Carlsbad, CA).  Confocal imaging was 
performed using a TCS SP8 laser-scanning confocal microscope equipped a 20X 
objective (HCPL APO 20X/0.70 NA), Leica Microsystems) with lasers for excitation 
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at 405nm, 458nm, 488nm, 514nm, 543nm, and 633nm wavelengths. (Leica 
Microsystems, Inc., Bannockburn, IL). 
3.2.12: Real time PCR 
Liver myeloid subpopulations were sorted as shown (Supplemental Fig. 3.1) 
at the MD Anderson Flow Cytometry and Cellular Imaging Core Facility (FCCIF). 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, MD) and reverse 
transcribed using the SuperScript IV Reverse Transcriptase kit (Thermo). Taqman 
real-time PCR was performed on a Via 7 Real Time PCR System (Applied 
Biosystem, CA) as previously described (212,213). Levels of il27-p28, ifng, and 
tnfa were expressed as the fold change using the ΔΔCt method. 
3.2.13: Cytometric bead array  
Bone marrow derived monocytes were isolated from wildtype mice using a 
Monocyte Isolation Kit (Miltenyi Biotech) and were stimulated in vitro with α4-1BB 
(3H3) antibody for 48 hours. Cytokine release was quantified using a 
Th1/Th2/Th17 Cytometric Bead Array kit (BD) as per manufacturer’s instructions.   
3.2.14: Statistical analysis 
All statistics were calculated using Graphpad Prism Version 6 for Windows.  
Statistical significance was determined using a two-sided Student’s T test applying 
Welch’s correction for unequal variance. Graphs show mean ± standard deviation 
unless otherwise indicated.  P-values less than 0.05 were considered significant.  
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3.3: Results 
3.3.1: Disparate effects of CTLA-4 and PD-1 checkpoint blockade on α4-
1BB-mediated hepatotoxicity 
To determine the potential for currently approved checkpoint blockade 
antibodies (αCTLA-4, αPD-1) to ameliorate 4-1BB agonist antibody induced liver 
pathology, mice were treated with three administrations of checkpoint antibody, 
α4-1BB alone, α4-1BB in combination with αCTLA-4 or αPD-1, or triple 
combination therapy. At the peak of hepatic injury, sixteen days after the initiation 
of treatment (Supplemental Fig. 3.1A), mice were bled and serum was analyzed 
for liver transaminases including alanine aminotransferase (ALT; Reference mean 
26.5 ± 5) and aspartate aminotransferase (AST; Reference mean 43.2 ± 9.5)(215).  
As noted previously, co-administration of αCTLA-4 significantly decreased serum 
transaminase levels compared to α4-1BB monotherapy (209), whereas dual 
therapy with α4-1BB and αPD-1 significantly increased transaminase levels (Fig. 
3.1A) (216).  The protective effect of αCTLA-4 therapy was lost when given in 
combination with both α4-1BB and αPD-1, suggesting that exacerbation of 
hepatitis by αPD-1 dominates over the capacity of αCTLA-4 to limit it.  As triple 
combination therapy failed to alleviate hepatic damage, we sought to define the 
cellular mechanisms by which CTLA-4 blockade acted to limit α4-1BB 
hepatotoxicity. 
4-1BB agonist administration drove robust CD3+ T cell infiltration of the liver 
including > 2-fold increases in cytotoxic CD8 T cells relative to untreated animals 
or those receiving CTLA-4 blockade (Fig. 3.1B, Supplemental Fig. 3.1B), but did 
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not significantly impact infiltration of bulk CD4+ T cells (CD4+CD3+) or CD4+ 
effector T cells (CD4+CD3+FoxP3-) (Supplemental Fig. 3.2A, and B).  Functionally, 
the majority of these infiltrating T cells bore the recently defined 
Eomesodermin+KLRG1+ signature of the cytotoxic ThEO (CD4) and TcEO (CD8) 
phenotype that are critical for anti-tumor immunity by exhibiting elevated 
cytotoxicity compared to their Th1/Tc1 counterparts, and likely play a significant 
role in mediating liver damage (Supplemental Fig. 3.2 C,D,E)(213,217-219).  
Further, the addition of CTLA-4 blockade to α4-1BB treatment reduced the 
frequency of T cell infiltration into the liver versus α4-1BB alone (Fig. 3.1B).  
Whereas the overall CD3 density was reduced in α4-1BB/αCTLA-4 combination 
treated animals, no changes in the CD4 and CD8 frequencies within the infiltrating 
T cell pool, nor in the percentage of cells adopting the ThEO/TcEO phenotype were 
observed (Fig. 3.1B, Supplemental Fig. 3.2D,E). Consistent with the overall 
decrease in T cell infiltration, inflammatory foci (Fig. 3.1C) and clusters of CD8 T 
cells in the liver parenchyma also decreased when αCTLA-4 was co-administered 
with α4-1BB , but were exacerbated by triple combination therapy (Fig. 3.1D, E).  
Overall, αCTLA-4 co-administration with α4-1BB significantly decreased the 
severity of inflammation, necrotic regions, and CD8 T cell infiltration in liver 
parenchyma as indicated by a reduced pathology score (Fig. 3.1E,F).  
To test whether the ability of CTLA-4 blockade to reduce liver pathology 
was specific for 4-1BB agonist therapy, we also tested αCTLA-4 in combination 
with antibodies targeting the TNF receptor CD40. Co-stimulation through CD40 
induces an acute and transient hepatic injury that peaks within a week of antibody 
administration and declines thereafter, whereas 4-1BB agonists induced a chronic, 
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and persistent hepatic pathology as measured by maintained elevation of serum 
transaminases over the 16-day study (Fig. 3.1G).  Further, in contrast to α4-1BB, 
αCD40-induced liver damage was not ameliorated by co-administration with 
αCTLA-4 (Fig. 3.1H).   
These data suggest that 4-1BB agonist antibodies mediate chronic liver 
pathology through a mechanism distinct from CD40 activation.  Although CTLA-4 
blockade can ameliorate 4-1BB agonist induced hepatitis through reduction of T 
cell infiltration; this mechanism fails to impact liver injury resulting from αCD40 or 
α4-1BB/αPD-1 combination therapy. 
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Figure 3.1 
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Figure 3.1: Combination immunotherapy augments α4-1BB mediated 
hepatotoxicity. Mice were administered α4-1BB, αCTLA-4, or αPD-1 antibodies 
alone or in combination within 3 day intervals (days 0, 3, and 6). Mice were bled 
16 days after initiation of therapy and sacrificed to measure liver immune infiltrates 
by flow cytometry.  A) Serum levels of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) were measured upon sacrifice as units of 
enzyme/liter of blood.  B)  Immune infiltrates within perfused livers of treated mice 
were measured by flow cytometry.  Percent of CD3+ cells was calculated as a 
fraction of liver CD45+ cells.  Frequency of CD8+ T cells was calculated as a 
percent of CD3+ cells. C) Hemotoxylin and Eosin (H&E) staining or 
immunohistochemistry (IHC) targeting CD8 (D) was performed on sectioned liver 
tissues from treated mice 16 days after initiation of therapy.  E) Sections were 
assigned a clinical score by a pathologist based on the number of inflammatory 
cells in the portal triad, central vein, or parenchyma and (F) CD8+ infiltration was 
enumerated per section. G)  Mice administered either α4-1BB or αCD40 agonist 
antibodies were bled 8 or 16 days after initiation of therapy and serum levels of 
ALT and AST were analyzed.  H) Mice were administered either αCD40 agonist 
antibodies alone or in combination with αCTLA-4 blockade.  Mice were then bled 
at the peak of αCD40-mediated liver damage (D8) in order to assess serum 
transaminase levels.  Each point in A, and B represents an individual mouse.  
Micrographs in C and D were imaged at 20X magnification.  Data were pooled from 
≥ 3 experiments with 5 mice per group.  Bars represent mean ± SD.  Statistical 
significance was calculated using a two-sided Student’s T test applying Welch’s 
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correction for unequal variance.  ns, not significant; *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001.    
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3.3.2: 4-1BB agonists initiate liver pathology through activation of liver-
resident myeloid cells. 
Given the differential liver toxicities associated with 4-1BB agonists and 
CD40 agonists, we sought to uncover the relative contribution of the myeloid and 
T cell pools to 4-1BB agonist-induced liver damage.  Whereas CD40 is exclusively 
expressed by myeloid cells (220), 4-1BB can be expressed on both T cell, NK cell 
and myeloid populations (205,213,221,222), and the relative contribution of each 
of these to liver pathology remains undefined. 
To reveal the relative contribution of the myeloid versus lymphocyte 
compartments to α4-1BB induced hepatotoxicity, wildtype or 4-1BB-/- mice were 
administered a sublethal dose of radiation sufficient to eliminate their endogenous 
lymphocytes.  Twenty-four hours after irradiation, splenic lymphocytes from 
wildtype or 4-1BB-/- mice were magnetically sorted and adoptively transferred into 
irradiated wildtype or 4-1BB-/- hosts.  In this way, ablation of the lymphoid pool, but 
not the radio-resistant myeloid pool, allowed us to specifically target 4-1BB on 
either T cells or myeloid cells.  Mice then received 4-1BB agonist therapy as 
previously described.  Mice receiving WT to WT splenocyte transfers (myeloid 4-
1BB+, lymphocyte 4-1BB+) clearly manifested ALT elevation in response to 4-1BB 
agonist antibody treatment compared to WT to WT transfers administered isotype 
control antibodies or 4-1BB-/- mice receiving 4-1BB-/- cells in conjunction with α4-
1BB (Fig. 3.2A), while AST elevation, which is always less affected by α4-1BB, 
showed modest elevation as well (Supplemental Fig. 3.3A).  Wildtype mice that 
received splenocytes from 4-1BB-/- mice (myeloid 4-1BB+, lymphocyte 4-1BB-) 
were not significantly protected against ALT elevation, but did show reduced 
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elevation of AST.  On the other hand, 4-1BB-/- mice receiving splenocytes from 
wildtype mice (myeloid 4-1BB-, lymphocyte 4-1BB+), were fully protected from ALT 
elevation and showed no significant elevation of AST relative to mice lacking 4-
1BB only on T cells.  Thus, when 4-1BB was absent from the myeloid 
compartment, α4-1BB could no longer trigger hepatotoxicity suggesting a 
requirement for myeloid 4-1BB activation to initiate a liver inflammatory cascade.  
The absence of 4-1BB on T cells did not appear deterministic for liver inflammation, 
but the modest reductions in transaminases relative to WT mice suggested a 
contributory role for 4-1BB on T cells as well. 
Given our prior data, we investigated the role of myeloid cells in initiating 
α4-1BB induced liver pathology.  We found that, in comparison to untreated livers, 
α4-1BB therapy increased the frequency of F4/80+ macrophages within the liver 
parenchyma which was significantly reduced by combining αCTLA-4 with α4-1BB 
(Fig. 3.2B, C, D).  Interestingly, combination therapy favored accumulation of 
F4/80+ cells within the perivascular space compared to infiltration into the tissue 
parenchyma (Fig. 3.2D). The expanded liver macrophages consist of tissue-
resident Kupffer cells, defined by expression of the adhesion receptor F4/80, that 
remain relatively quiescent within healthy liver, are replenished by bone marrow-
derived myeloid precursors or via low-level homeostatic proliferation, and are 
functionally and phenotypically distinct from circulating CD11b+F4/80- monocytes 
(223).  Further, Kupffer cells can be sub-classified into populations of 
CD11b+CD68- myeloid cells specialized for cytokine production, CD11b-CD68+ 
phagocytic macrophages and CD11b+CD68+ cells with intermediate phagocytic 
activity and cytokine expression (224).  In naïve mice, we were only able to detect 
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clear 4-1BB expression on monocytes by flow cytometry (Supplemental Fig. 3.3B); 
however, 4-1BB expression was detected on both F4/80- monocytes and on a 
small percentage of F4/80+ Kupffer cells in situ by immuno-fluorescence (Fig. 
3.2E).  The Kupffer cell phenotype is sensitive to disruptive procedures used to 
prepare livers for flow cytometry, likely explaining the lower resolution of flow 
cytometry.  Both methods, however, showed that 4-1BB was readily induced on 
Kupffer cells by inflammatory cytokines such as TNFα which are plentiful during 
α4-1BB-induced liver injury, with flow cytometry confirming the CD11b-CD68+ and 
CD11b+CD68+ sub-populations as the primary targets (Fig. 3.2E, Supplemental 
Fig. 3.3C).  To assess the origin of these Kupffer cell populations, as well as the 
plasticity of infiltrating bone marrow-derived monocytes, we adoptively transferred 
congenically labelled bone marrow myeloid progenitor cells and administered α4-
1BB to the recipient mice.  In response to 4-1BB activation, these monocytes 
expanded in the blood and infiltrated the liver (Supplemental Fig. 3.3D).  A majority 
of these liver-infiltrating cells remained phenotypically monocytes (CD11b+F4/80- 
); however, some capacity to differentiate into CD11b-CD68+ and CD11b+CD68+ 
subpopulations of Kupffer cells was observed (Fig. 3.2F).  This is consistent with 
recent literature showing that while most Kupffer cells originate from embryonically 
derived erythro-myeloid progenitor (EMP) cells, some capacity of bone-marrow 
derived monocytes to replenish these populations does exist(225,226). 
Based on these findings, we hypothesize that bone marrow-derived 
monocytes infiltrate the liver and, in response to 4-1BB activation, initiate a 
cascade of inflammatory cytokine production (Supplemental Fig. 3.3E) which 
triggers 4-1BB upregulation by resident Kupffer cells allowing them to respond in 
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turn to the agonist antibody(Supplemental Fig. 3.3C).  Our data, however, does 
not rule out a minor contribution of 4-1BB+ monocytes differentiating into resident 
cells with a Kupffer phenotype themselves and contributing to the response 
directly. 
Further, all three Kupffer cell subsets showed signs of activation in response 
to 4-1BB agonist antibody (Fig. 3.2G). Increases in the CCR5+ fraction of the 
CD11b+CD68- and CD11b-CD68+ subpopulations by approximately 2-fold 
suggests that these cells are either new emigrants or derived from them, or, 
alternatively that they are re-distributing within sub-compartments of the liver.  Both 
possibilities are consistent with increased infiltration into the perivascular space 
that we observed (227,228).  CCR5 expression decreased, however, on the 
CD11b+CD68+ subset, which may be a result of receptor downregulation by recent 
emigrants from the bone marrow as we observed no evidence of elevated in situ 
proliferative expansion by Ki67.  Moreover, all three subsets of F4/80+ cells 
increased MHC-II expression, further suggesting that these populations are 
activated by 4-1BB antibody consistent with published literature demonstrating that 
this activation promotes enhanced co-stimulatory capacity (213,221). 
We next sought to confirm the ability of the cytokine-producing myeloid 
populations to mediate liver damage during the course of α4-1BB therapy, as well 
as to determine what effector molecules these populations produce to mobilize 
immune responses leading to hepatic damage.  Within the F4/80 positive 
population, CD68+ (F4/80+CD11b-CD68+), CD11b+ (F4/80+CD11b+CD68-), and 
CD11b+CD68+ (F4/80+CD11b+ CD68+) cells as well as CD11b+F4/80- monocytes 
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were FACS sorted on day 7 from the livers of treated mice (Supplemental Fig. 3.1), 
and RNA was isolated from each population for quantitative real time PCR.  We 
found that, compared to αCD40 treatment which induced significant activation and 
IFNγ production in CD11b+CD68+ Kupffer cells, the F4/80+CD11b+CD68- and 
F4/80+CD11b+CD68+ myeloid cells were the predominant cytokine producers with 
little or no contribution from the CD11b- subset within the livers of α4-1BB treated 
mice. Within the two CD11b+CD68- subsets, we observed approximately 20-fold 
increased expression of IL-27-p28 following 4-1BB agonist therapy compared to 
treatment-naïve mice. In contrast, the CD11b-CD68+ subset was the primary 
source of interferon-γ (Fig. 3.2H). Moreover, both CD11b+ subsets of Kupffer cells 
produced the majority of TNFα.  Notably, the cytokine producing subsets of 
myeloid cells produced less IL-27 and TNFα in mice receiving the α4-1BB/αCTLA-
4 combination therapy compared to mice receiving α4-1BB monotherapy. While 
the CD11b-CD68+ subset demonstrated roughly 50-fold increases in IL27-p28 
expression relative to its baseline level during α4-1BB/αCTLA-4 combination 
therapy, the delayed cycle within which transcripts were detected (~cycle 37 
versus ≤cycle 26 for the cytokine-producing subsets) suggests that the actual 
quantity of transcript present in these cells was extraordinarily small.     
Together, these data suggest, α4-1BB-mediated inflammatory 
hepatotoxicity initiates at the myeloid level via activation of tissue-resident Kupffer 
cells and, potentially, infiltrating monocytes.   All three subsets of Kupffer cells, and 
to a lesser extent monocytes, showed signs of activated antigen presentation, and 
both CD11b+ cytokine-producing subsets increased production of IL-27.  Co-
administration of CTLA-4 blockade reduced inflammatory cytokine production in 
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these subsets, consistent with the reduced transaminase elevation observed in 
those mice. 
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Figure 3.2 
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Figure 3.2: Administration of 4-1BB agonist antibodies initiates liver 
pathology through activation of liver-resident myeloid cells. A) Mice were 
sublethally irradiated (500 rads) before administration of 2X106 CD90+ 
splenocytes. Wildtype mice either received splenocytes from wildtype mice 
(WTWT) or from 4-1BB-/- mice (4-1BB-/-WT) and 4-1BB-/- mice received 
splenocytes from wildtype mice (WT4-1BB-/-) or from 4-1BB-/- mice (4-1BB-/-4-
1BB-/-). Mice were subsequently treated with three round of isotype control or α4-
1BB immunotherapy.  Treated mice were then bled 16 days after the first 
administration of therapy and serum ALT was measured.  B)  Frequency of F4/80+ 
myeloid infiltration into perfused livers based on flow cytometry of lymphoid-replete 
wildtype mice administered either α4-1BB therapy alone or in combination with 
αCTLA-4 checkpoint blockade. Myeloid infiltration shown as the percent of F4/80+ 
cells as a fraction of total CD45+ cells. C) Immunohistochemistry staining for F4/80+ 
was performed on sectioned liver tissues from treated mice 16 days after initiation 
of therapy D) Quantification F4/80+ cellular infiltrates based on IHC staining of liver 
sections. Individual F4/80+ cells were enumerated within the liver parenchyma or 
perivascular space.  E) Confocal imaging of myeloid immune infiltrates in naïve or 
α4-1BB-treated livers 16 days after initiation of treatment F) Phenotypic 
characterization of congenically marked, adoptively transferred bone marrow-
derived myeloid cells into perfused livers and blood based on flow cytometry of 
mice administered α4-1BB therapy. G) Frequency of inflammatory/activation 
markers based on flow cytometry of perfused livers from treated mice based on 
three subsets of liver-resident macrophages: CD11b+CD68- cytokine-producing 
Kupffer cells, CD11b+CD68+ cytokine-producing/phagocytic Kupffer cells, and 
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CD11b-CD68+ phagocytic Kupffer cells. H) Gene expression from individual 
myeloid populations was calculated at day 7 post treatment initiation using real-
time PCR analysis with gapdh as the endogenous control. Each point in A and B 
represents an individual mouse.  Micrographs in C were imaged at 20X 
magnification.  Micrographs in E were imaged using a 20X air objective.  Insets for 
magnified using 2X magnification. Gene expression was calculated using Taqman 
primers via the ΔΔCt method. Data were pooled from ≥ 2 experiments with 5 mice 
per group.  Bars represent mean ± SEM.  Statistical significance was calculated 
using a two-sided Student’s T test applying Welch’s correction for unequal 
variance.  ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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3.3.3: Interleukin 27 is a critical regulator of liver inflammation. 
In addition to the above, we previously reported that IL-27 acts to polarize 
T cells to the cytotoxic ThEO/TcEO phenotype (213), and therefore hypothesized 
that it may play a role in triggering α4-1BB-induced hepatic damage.  To evaluate 
the contribution of IL-27 to immune-mediated hepatotoxicity, mice lacking the Ebi3 
subunit of IL-27 (EBI3-/-) or mice lacking the IL-27 receptor alpha subunit (IL27Rα-
/-) were treated with α4-1BB therapy followed by analysis of transaminase levels.  
Compared to wildtype mice, EBI3-/- and IL27Rα-/- mice treated with 4-1BB agonists 
failed to develop liver damage as measured by serum ALT and AST (Fig. 3.3A). 
Remarkably, the high-grade elevation of liver transaminases resulting from triple 
combination α4-1BB/αCTLA-4/αPD-1 therapy was also nearly completely 
abrogated in EBI3-/- mice.  Moreover, abrogation of the IL-27 pathway did not 
significantly impact basal 4-1BB expression nor TNFα induced expression on liver-
resident myeloid populations (Supplemental Fig. 3.4A, B), suggesting that EBI3-/- 
mice were equally capable of receiving 4-1BB signal.  
In mice lacking the IL-27/IL-27R pathway, CD3+ T cell infiltration of the liver 
was reduced (Fig. 3.3B) as were both the frequency and density of cytotoxic CD8+ 
cells (Fig. 3.3C).  Further, the frequency of CD4 effector T cells appeared minimally 
affected by knockout of the IL-27 pathway (Supplemental Fig. 3.4C). While the 
percent of CD4+Eomes+KLRG1+ ThEO phenotype cells (Supplemental Fig. 3.4D), 
and CD8+ TcEO phenotype T cells were minimally affected by loss of IL-27, the 
total numbers of the highly inflammatory TcEO population within liver infiltrates 
were significantly diminished absent functional IL-27 signaling (Fig.3.3D).   
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Taken together, these data demonstrate a critical requirement for the 
inflammatory cytokine IL-27 in mediating 4-1BB agonist antibody-induced 
hepatotoxicity as well as for recruitment and/or expansion of hepatogenic T cells 
into the liver.  
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Figure 3.3 
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Figure 3.3: Interleukin 27 is a critical regulator of 4-1BB agonist-induced liver 
inflammation. Wildtype mice or mice lacking the Ebi3 subunit of the IL-27 cytokine 
complex (EBI3-/-) or the IL-27 receptor alpha subunit (IL27Rα-/-) were treated for 
three rounds of α4-1BB agonist immunotherapy before analysis of serum 
transaminase levels and hepatic immune infiltrates 16 days after initiation of 
treatment. A) Serum levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were measured upon sacrifice as units of enzyme/liter of 
blood volume. B) Quantification of immune infiltrates within perfused livers of 
treated mice was measured by flow cytometry.  Frequency of CD3+ cells was 
calculated as a percent of total CD45+ cells in the liver. C) Frequency of CD8+ T 
cells was calculated as a percent of CD3+ cells. Total numbers of cells were taken 
as number of CD3+ or CD3+CD8+ cells within perfused livers.  D)  Quantification of 
percent and total numbers of TcEO T cell infiltration within the livers of treated 
mice.  Frequency of TcEO was calculated based on the percent of CD3+CD8+ T 
cells expressing Eomesodermin (Eomes) and KLRG1. Each point within each 
graph represents an individual mouse. Data were pooled from ≥ 2 experiments 
with 5 mice per group.  Bars represent mean ± SD.  Statistical significance was 
calculated using a two-sided Student’s T test applying Welch’s correction for 
unequal variance.  ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001. 
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3.3.4: Regulatory T cells restrict 4-1BB agonist antibody induced liver 
pathology 
Given the ability of myeloid cells to activate T cell responses, coupled with 
the capacity of IL-27 to act as an inflammatory mediator of hepatic damage with 
pleotropic effects on helper T cell polarization, Treg suppression, and T cell 
trafficking (229-231), and the prolonged inflammatory response induced by α4-
1BB (Fig. 3.1G), we investigated the role of T cells in propagating α4-1BB-
mediated liver damage.  To assess the relative contribution of the T cell pool in 
mediating hepatotoxicity, we administered α4-1BB to mice lacking the β2 
microglobulin subunit of the major histocompatibility (MHC) I complex (β2M-/-) or 
mice lacking all H2-A/E MHC genes (MHCII-/-).  These mice are deficient in antigen 
presentation to CD8 and CD4 T cells respectively, leading to a failure of these cells 
to complete thymic positive selection and enter the periphery.  Even though these 
mice exhibited similar patterns of 4-1BB expression compared to wildtype mice 
(Supplemental Fig. 3.5A,B), elevation of liver ALT and AST levels was completely 
abrogated in α4-1BB-treated β2M-/- mice, confirming the role of CD8+ T cells in 
mediating the bulk of the liver damage (Fig. 3.4A) (210).  To separate the 
possibilities that this effect may be due to absent CD8 T cell responses and/or to 
defective antigen presentation, mice were sub-lethally irradiated and CD8+ 
splenocytes from wildtype mice were transferred into β2M-/- mice. We 
hypothesized that if the lack of CD8 T cells in these mice was the sole cause of 
the abrogated hepatotoxicity, then supplying wildtype CD8+ T cells would reinitiate 
toxicity. Interestingly, supplementation of WT CD8+ T cells into β2M-/- mice did not 
abrogate the resistance of these animals to liver damage when challenged with 4-
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1BB antibody (Fig. 3.4B). This suggests that not only are CD8 T cells required to 
effect 4-1BB agonist-induced liver injury, but that antigen presentation on MHC 
Class I is also necessary. This further indicates that hepatitis-inducing CD8 T cells 
are being activated by 4-1BB-activated myeloid cells in an antigen-specific 
manner.   Intriguingly, impairing the CD4 response in MHCII-/- mice significantly 
escalated liver damage, denoted by approximately 1.5-2-fold increases in serum 
AST (176 vs. 87; p=0.0008) and ALT (108 vs. 84; p=0.0244) levels in MHCII-/- mice 
compared to α4-1BB treated wildtype mice (Fig. 3.4A).   
We next hypothesized that exacerbation of hepatotoxicity in MHCII-/- mice 
stemmed not from dysregulation of effector T cells responses, but from elimination 
of Treg cells, leading to loss of immune homeostasis in the liver. We made the 
related observation that there was a 2-fold increase in the fraction of Foxp3+ 
regulatory T cells in the livers of α4-1BB compared to untreated mice (Fig. 3.4C) 
suggesting that Treg expansion might be acting to limit hepatitis. Using flow 
cytometry based analysis, however, we did not see any significant difference in 
overall Treg infiltration in the liver of α4-1BB alone treated mice compared to 
combination treated mice. Interestingly, probing cellular localization using 
immunohistochemistry revealed increased infiltration of Treg in the liver 
parenchyma when αCTLA-4 was co-administered with α4-1BB, which is consistent 
with a reduction of inflammatory foci in the liver parenchyma of mice treated with 
αCTLA-4 and α4-1BB in combination (Fig. 1C,E).  To validate a role for Tregs in 
limiting α4-1BB-induced liver toxicity, we treated mice expressing the diphtheria 
toxin (DT) receptor (DTR) under control of the Foxp3 promoter (Foxp3-DTR) in 
which Foxp3+ regulatory T cells can be depleted upon administration of DT.  
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Briefly, DT was administered 2 days before α4-1BB therapy, and continued until 
the end of treatment for complete and sustained Treg depletion.  Treg depletion 
was successful based on analysis of blood three days before serum analysis 
(Supplemental Fig. 3.5C). Consistent with our hypothesis, depletion of Tregs 
significantly aggravated α4-1BB induced liver damage, increasing AST and ALT 
levels 5-6-fold, and eliminating the ability of αCTLA-4 to dampen liver damage (Fig. 
3.4D).  This effect was not due to administration of DT, as DT alone did not 
significantly impact transaminase levels.  Moreover, Treg adoptive transfer prior to 
therapy limited transaminase elevation, suggesting that Treg cells are critical 
suppressors of inflammation during α4-1BB treatment.  Of note, while the CTLA-4 
antibodies used here are capable of depleting Tregs in the context of tumor 
microenvironments, they do not deplete peripheral Tregs, and may sometimes 
expand them, due to the low densities of the FcγRIV receptor in these tissues 
(232). 
Taken together this data suggests a critical role of CD8 T cell activation in 
mediating α4-1BB liver damage.  Antigen presentation was also required 
suggesting hepatogenic CD8 T cells are liver tissue-antigen specific.  Further, Treg 
cells play a critical role in protecting the liver from CD8-mediated injury 
downstream of α4-1BB. 
 
 
128 
 
 
 
Figure 3.4 
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Figure 3.4: Regulatory T cells suppress 4-1BB agonist antibody induced liver 
pathology. A) Wildtype mice or mice lacking MHC Class I expression (β2M-/-) or 
all MHC Class II alleles (MHC-II-/-) were treated for three rounds with α4-1BB 
agonist antibody (days 0, 3, and 6) before mice were bled for serum liver enzyme 
analysis 16 days after beginning treatment.  Serum ALT and AST were measured 
upon sacrifice as units of enzyme/liter of blood. B) Mice were sub-lethally irradiated 
(500 rads) before administration of 2X106 CD8+ splenocytes. Wildtype mice or 
β2M-/- mice received splenocytes from wildtype mice (WT CD8WT) or (WT 
CD8β2M-/-) respectively. Mice were subsequently treated with three round of α4-
1BB immunotherapy.  Treated mice were then bled 16 days after first 
administration of therapy and serum ALT and AST were measured. C) Frequency 
of regulatory T cell (Treg) infiltration into the perfused livers of mice 16 days after 
initiation of therapy was quantified by flow cytometry as the percent of Foxp3+CD4+ 
cells as a fraction of total CD4+ T cells. D) Immunohistochemistry (IHC) targeting 
regulatory T cells was performed on sectioned liver tissues from mice 16 days after 
initiation of therapy.  E) Sections were quantified for Treg infiltration in the 
perivascular and parenchyma area of liver and was enumerated per section. F) 
Mice received 5X105 CD3+CD4+CD25+ splenocytes FACS-sorted from naïve mice 
one day prior to treatment. Concurrently, mice expressing the diphtheria toxin 
receptor under control of the Foxp3 promoter (Foxp3-DTR) were administered 10 
µg/kg body weight of diphtheria toxin one day prior to initiation of therapy and every 
three days thereafter until completion of the experiment.  Data were pooled from ≥ 
2 experiments with 5 mice per group.  Bars represent mean ± SD.  Statistical 
significance was calculated using a two-sided Student’s T test applying Welch’s 
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correction for unequal variance.  ns, not significant; *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001.     
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3.3.5: CCR2 and CXCR3 are differentially required for liver and tumor T cell 
trafficking 
Given the ability of IL-27 to induce chemokine receptor expression 
(233,234), the reduced immune infiltrate in the liver in the absence of IL-27, and 
the reduced myeloid presence in mice treated with α4-1BB/αCTLA-4 co-therapy, 
we hypothesized that 4-1BB agonist therapy might alter T cell trafficking patterns 
into the tissue via chemokine modulation.  Given the differential expression 
patterns of chemokine receptors on T cells capable of homing into tumor tissue 
versus liver (228,235), we sought to determine whether anti-tumor immunity could 
be separated from hepatitis based on differential homing.  We challenged either 
wildtype, CCR2-/-, CXCR3-/-, or CCR5-/- mice subcutaneously with 3X105 murine 
B16 melanoma cells expressing the ovalbumin antigen (B16-Ova).  Mice were then 
treated with 4-1BB agonist and assessed for serum transaminase elevation and 
infiltration.  CXCR3 is critical for driving IFNγ-dependent T cell trafficking into 
tumors, while CCR5 remains the predominant trafficking mechanism into the liver; 
however, CXCR3 can regulate liver chemotaxis in response to injury (236).   
CCR2, in contrast, minimally impacts T cell trafficking to liver even in the context 
of viral infection.  Intriguingly, following 4-1BB agonist antibody therapy, CCR2-/- 
mice exhibited significantly reduced AST and ALT serum levels, while CXCR3-/- 
mice showed significantly reduced ALT levels and a trend towards lower AST 
levels (p=0.08) (Fig. 3.5A). In contrast, CCR5-/- showed no significant reduction in 
the liver damage induced by α4-1BB. Ablation of these chemokine receptors 
individually failed to impact the ability of 4-1BB agonist therapy to mediate rejection 
of subcutaneous melanoma (Fig. 3.5B), implying either that they are not required, 
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or that sufficient redundancy exists to preserve responses in the tumor setting. 
Moreover, removing these chemokine receptor pathways did not significantly 
affect recruitment of antigen-specific T cells into the tumor (Fig. 3. 5C).  Of note, 
the apparent lack of significant increase in tetramer frequency in response to α4-
1BB therapy here is largely a function of the potency of 4-1BB agonists against 
these B16-Ova tumors.  In the treated animals, both wild-type and chemokine 
knockout, the therapy is so effective that a significant number of mice have 
eradicated their tumors leaving only a small remnant of Matrigel and few, if any, 
antigen-specific CD8 T cells.  It has been demonstrated across multiple tumor 
microenvironments that increased CD8/Treg ratios correlate with more successful 
responses to immune-based therapies (94,237,238).  We found that the magnitude 
of elevation of CD8/Treg ratios in wildtype, CCR2-/-, CXCR3-/-, and CCR5-/- mice 
were not significantly different providing additional evidence that loss of a single 
chemokine receptor pathway does not impact anti-tumor immune responses (Fig. 
3.5D, Supplemental Fig. 3.5D).  Interestingly, within the liver, abrogation of CCR5 
significantly increased the CD8/Treg ratio.  While this may be beneficial in the 
tumor setting, an increased ratio within the liver may account for the maintenance 
of elevated transaminase elevation in the CCR5 knockout mice (Fig. 3.5A).  The 
lack of an increase in transaminases in these CCR5 knockout mice, we 
hypothesize, suggests that Treg may rely on production of soluble factors such as 
TGF-β, rather than on cell-contact dependent interactions to maintain liver 
homeostasis, and therefore can maintain tissue tolerance even when at a modest 
numerical disadvantage relative to effectors. 
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Taken together, these data suggest that immune infiltration into the liver and 
tumor can be uncoupled through abrogation of chemokine receptor signaling.  
Further, CCR2 and CXCR3 appear to be critical mediators of α4-1BB induced 
hepatoxicity-mediating T cell trafficking, while disengaging these pathways does 
not significantly impact the ability of α4-1BB therapy to generate potent anti-tumor 
immunity.   
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Figure 3.5 
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Figure 3.5: The chemokine receptors CCR2 and CXCR3 contribute to 4-1BB 
agonist-induced liver pathology. Wildtype mice or mice lacking specific 
chemokine receptors (CCR2-/-, CXCR3-/-, or CCR5-/-) were subcutaneously 
implanted on the right flank with 3X105 B16 melanoma tumor cells expressing the 
ovalbumin antigen (B16-Ova). At three-day intervals after initial tumor challenge 
(days 3, 6, and 9) mice were treated with antibody immunotherapy delivered i.p. in 
combination with an irradiated tumor vaccine (FVAX) administered 
subcutaneously on the left flank. Mice were bled for serum liver enzyme analysis 
16 days after treatment initiation. Mice were then sacrificed and perfused livers 
and tumors were extracted, weighed, and processed for FACS analysis. A) Serum 
ALT and AST were measured upon sacrifice as units of enzyme/liter of blood 
volume. B) Upon sacrifice, tumors were harvested and weighed.  C) Tumor 
infiltration of Ova-specific CD8+ T cells was determined by staining tumor 
infiltrating lymphocytes (TIL) with fluorescently labeled Ova257-254/Kb (SIINFEKL) 
tetramer and antibodies to CD8.  Data are expressed as the total number of 
tetramer positive cells per milligram of tumor. D) Quantification of CD8/Treg ratios 
within the tumor and liver were calculated by dividing the number of CD8+CD3+ 
cells by the number of CD4+Foxp3+ cells found within the tissue infiltrate. Data 
were pooled from ≥ 2 experiments with 5 mice per group.  Bars represent mean ± 
SD.  Statistical significance was calculated using a two-sided Student’s T test 
applying Welch’s correction for unequal variance.  ns, not significant; *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.       
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Figure 3.6 
 
Figure 3.6: Mechanistic model of 4-1BB agonist antibody-mediated 
hepatotoxicity. 
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3.4: Discussion 
While the field of immunotherapy has experienced unprecedented growth 
due to the success of immune checkpoint blockade, clinical translation of the most 
efficacious mono- and combination therapies from pre-clinical models has been 
limited by immune toxicities.  4-1BB agonist antibodies are among the most 
effective immunotherapeutics across pre-clinical models of cancer (205).  Severe 
off-target liver damage in early Phase I trials; however, has limited the clinical 
progression of highly active 4-1BB antibodies (211).  Effective prophylaxis, 
biomarker prediction, or management of this toxicity, except through highly 
attenuated dosing, has proven challenging due to a lack of mechanistic 
understanding of underlying cellular and molecular mechanisms.  Efforts at 
development of 4-1BB agonist antibodies with limited toxicity are ongoing; 
however, no 4-1BB agonist has advanced beyond early Phase II trials.  In this 
manuscript, we sought to uncover the mechanisms driving 4-1BB agonist mediated 
liver pathology so that this knowledge may inform both antibody engineering and 
combination 4-1BB agonist trial design.  
The capacity of 4-1BB activation to potentiate CD8 T cell responses is 
widely accepted; however, we find that activation of liver myeloid cells, not T cells, 
is a critical initiating step that triggers hepatotoxicity. Following α4-1BB 
administration, bone marrow derived monocytes infiltrate the liver and, in response 
to 4-1BB activation, initiate a cascade of inflammatory cytokine production that 
triggers 4-1BB upregulation by resident Kupffer cells, allowing these cells to 
subsequently respond to agonist antibody.   Antigen presentation capacity 
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increased in multiple Kupffer cell populations based on MHC-II upregulation.  In 
addition, the cytokine-producing CD11b+ subsets increased production of IL-27 
more than 20-fold.  We find that this augmented IL-27 production is essential for 
the progression of liver inflammation, as neither EBI3-/- nor IL27Rα-/- mice showed 
any evidence of transaminase elevation in response to 4-1BB activation.  Despite 
the requirement for myeloid initiation, CD8 T cells mediate the actual liver injury, 
as mice lacking CD8s fail to develop transaminase elevation.  Prior studies indicate 
that mice expressing only CD8 T cells specific for an Ovalbumin-peptide/H2-Kb 
complex were also resistant to α4-1BB liver toxicity (210).  This observation, 
coupled with our own β2M-/- data, led us to question whether CD8 T cell activation 
downstream of myeloid 4-1BB activation was occurring via an antigen-dependent 
or independent mechanism.  Mice deficient in MHC Class I antigen presentation 
upon transfer of wildtype CD8 T cells failed to develop liver injury in response to 
α4-1BB, suggesting that hepatotoxic CD8 T cells recognize uncharacterized liver-
specific auto-antigens.  It is likely then, that 4-1BB activation of myeloid cells leads 
to enhanced presentation of liver tissue antigens and secreted IL-27 further 
provides a critical signal 3 for liver auto-reactive CD8 T cell activation.  The role of 
IL-27, in this context, could be direct co-stimulation of effector CD8 and/or inhibition 
of Treg suppressive activity.  These mechanistic insights suggest IL-27 blockade 
as a means to reduce to 4-1BB agonist liver toxicity; however, we have previously 
found IL-27 to play a critical role in effector T cell polarization downstream of α4-
1BB as well as in anti-tumor responses (213,239,240).   
Currently the only described mechanism to reduce 4-1BB agonist liver 
toxicity involves combination therapy with CTLA-4 blockade (209).  We confirm the 
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capacity of this combination to block 4-1BB agonist transaminase elevation.  Given 
this combination also shows therapeutic synergy and the capacity to limit αCTLA-
4 IRAE (94,209), it remains unfortunate that no trials have tested α4-1BB/αCTLA-
4 in patients.  In contrast, the α4-1BB/αPD-1combination has been tested in 
patients, but with very limited dosing regimens due to the capacity of αPD-1 to 
worsen α4-1BB-mediated hepatitis – an effect we also validated herein (216).  We 
hypothesized that the liver-protective effect of CTLA-4 blockade might also extend 
to α4-1BB/αPD-1combination therapy; however,  the effect of PD-1 blockade was, 
in fact, dominant and that triple combination treatment engendered severe 
transaminitis. Differential effects of CTLA-4 and PD-1 checkpoint blockade on α4-
1BB-mediated liver toxicity may be due, in part, to the expression patterns of each 
receptor on distinct immune populations, (high CTLA-4, moderate PD-1:Tregs, low 
CTLA-4, high PD-1; CD8) or on potential potency of these receptors to inhibit T 
cell activation/effector responses.  Alternatively, PD-1 blockade may decrease the 
suppressive capacity of Treg, and our data suggests that CTLA-4 blockade 
requires the presence of (functional) Treg to ameliorate 4-1BB agonist liver 
toxicity(241).  In the context of our model (Fig. 3.6), CTLA-4 blockade limited the 
accumulation of CD8 T cells and increased Treg in the liver parenchyma following 
4-1BB agonist administration, and thus attenuated resulting hepatotoxicity.  We 
also demonstrated an impact of αCTLA-4 co-administration on myeloid infiltration 
and effector function in the liver.  We observed distinct patterns of parenchymal 
versus perivascular infiltration of F4/80+ cells in each combination setting.  We 
hypothesize that it is the combination of accumulation of F4/80+ cells in the 
perivascular area, coupled with a capacity to infiltrate the parenchyma which 
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equals or exceeds that of 4-1BB agonist alone, that explains why the triple 
combination induces exacerbated liver toxicity.  Although perivascular infiltration 
increases with the αCTLA-4/α4-1BB combination, parenchymal F4/80+ cell density 
decreases, coincident with a decrease in CD8 T cells in this region and an increase 
in Treg.  Liver damage associated with significant transaminase elevation, in 
general, requires infiltration and damage within the liver parenchyma itself.  
Perivascular accumulation can represent expansion of resident cells with 
progenitor capacity and/or infiltration of monocytes and their subsequent 
differentiation into F4/80+ cells (a phenomenon for which we have demonstrated a 
limited capacity). 
We next considered whether the chemokine receptors governing entry of 
hepatitis-inducing T cells into the liver, versus migration of tumor-specific T cells 
into melanoma tumors might be sufficiently different to separate tumor immunity 
from hepatotoxicity.  We found that CCR2-/- mice, and to a lesser extent CXCR3-/- 
mice, were protected from 4-1BB agonist induced liver toxicity but were still 
capable of effectively combating B16-Ova tumors growing on the flank.  The impact 
of CCR2 knockout in abrogating liver toxicity remains enticing, as both small 
molecule (CCX872, ChemoCentryx; PF-04136309, Pfizer) and antibody 
(MLN1202, Millennium) antagonists for CCR2 are currently in clinical trials.  Given 
our findings, 4-1BB agonist antibodies administered in combination with CCR2 
inhibitors may prove to be a potent combination in promoting tumor regression 
while inhibiting off-target liver toxicity. 
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Supplemental Figure 3.1 
 
Supplemental Figure 3.1: Peak of 4-1BB mediate liver transaminase level and 
gating strategy for flow cytometry analysis of liver immune infiltrates. A) Mice 
were administered α4-1BB antibodies within 3 day intervals (days 0, 3, and 6) and 
were bled on days 7, 14 and 23 in order to assess serum transaminase levels. 
Each point in A represents data taken from an individual mice. B) Representative 
gating strategy to analyze CD8+ , CD4+ Teff, and CD4+ Treg T cell populations 
as well as F4/80+CD11b+CD68- , F4/80+CD11b+CD68+ , and F4/80+CD11b-
CD68+myeloid populations within perfused livers. 
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Supplemental Figure 3.2 
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Supplemental Figure 3.2: Representative flow cytometry analysis of liver 
immune infiltrates. A) Frequency of total CD4 (CD4+CD3+ ) and B) CD4 Teff 
(CD4+CD3+ Foxp3+ ) infiltrates into the perfused livers of treated mice 16 days 
after initiation of therapy. C) Representative gating strategy for analysis of 
Eomes+KLRG1+ TcEO (top) or ThEO (bottom) phenotype cells infiltrating the 
livers of treated mice. D) Quantification of TcEO (top) and ThEO (bottom) 
phenotype cells enumerated at the percent of CD3+CD8+ Eomes+KRLG1+ or 
CD3+CD4+ Foxp3- Eomes+KLRG1+ cells respectively that infiltrated perfused 
livers. Data were pooled from ≥ 2 experiments with 5 mice per group. Bars 
represent mean ± SD. Statistical significance was calculated using a two-sided 
Student’s T test applying Welch’s correction for unequal variance. ns, not 
significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Supplemental Figure 3.3 
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Supplemental Figure 3.3: Administration of 4-1BB agonist antibodies 
initiates liver pathology through activation of liver-resident myeloid cells. A) 
Mice were sublethally irradiated (500 rads) before administration of 2X106 CD90+ 
splenocytes. Wildtype mice either received splenocytes from wildtype mice 
(WTWT) or from 4-1BB-/- mice (4-1BB-/-WT) and 4-1BB-/- mice received 
splenocytes from wildtype mice (WT4-1BB-/- ) or from 4-1BB-/- mice (4-1BB-/-4-
1BB-/- ). Mice were subsequently treated with three rounds of isotype control or 
α4-1BB immunotherapy. Treated mice were then bled 16 days after first 
administration of therapy and serum AST was measured. Quantification of 4-1BB 
expression on naïve mice using flow cytometry analysis on myeloid cells from 
perfused livers either at B) basal level or C) after induction by TNFα stimulation. 
The liver myeloid populations were categorized into bone marrow derived CD11b+ 
F4/80-monocytes and three subsets of F4/80+ liver-resident macrophages: 
CD11b+CD68- cytokine-producing Kupffer cells, CD11b+CD68+ cytokine-
producing/phagocytic Kupffer cells, and CD11b-CD68+ phagocytic Kupffer cells. 
D) Quantification of congenically labelled and adoptively transferred bone marrow 
derived myeloid cells into perfused livers and blood based on flow cytometry of 
mice administered with α4-1BB therapy. Each point within graphs in A and D 
represents individual mice. C) Bone marrow derived monocytes were in vitro 
stimulated with α4-1BB (3H3) antibody for 48 hours and cytokine release was 
measured using a CBA kit. Data were pooled from ≥ 2 experiments with 5 mice 
per group. Bars represent mean ± SD. Statistical significance was calculated using 
a two-sided Student’s T test applying Welch’s correction for unequal variance. ns, 
not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Supplemental Figure 3.4 
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Supplemental Figure 4: Effects of IL-27 pathway inactivation on CD4 T cells. 
Quantification of 4-1BB expressions on EBI3-/- mice using flow cytometry analysis 
on myeloid cells from perfused livers at A) basal level or B) after 48 hours of TNFα 
stimulation. The liver myeloid population was categorized into bone marrow 
derived CD11b+ F4/80-monocytes and three subsets of liver-resident 
macrophages: CD11b+CD68- cytokine-producing Kupffer cells, CD11b+CD68+ 
cytokine-producing/phagocytic Kupffer cells, and CD11b-CD68+ phagocytic 
Kupffer cells. C) Frequency of effector CD4 T cells (CD3+CD4+ Foxp3- ) infiltrating 
the perfused livers of α4-1BB treated wildtype (WT), EBI3-/- , or IL27Rα-/-mice. D) 
ThEO phenotype cells (Eomes+KLRG1+ ) enumerated as the percent CD3+CD4+ 
Foxp3- cells that infiltrated perfused livers. Data were pooled from ≥ 2 experiments 
with 5 mice per group. Bars represent mean ± SD. Statistical significance was 
calculated using a two-sided Student’s T test applying Welch’s correction for 
unequal variance. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001. 
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Supplemental Figure 3.5 
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Supplemental Figure 5: Representative flow cytometry analysis of liver 
immune infiltrates. A) Quantification of 4-1BB expression on liver myeloid 
populations within β2M-/- mice or B) MHC-II-/- mice using flow cytometry analysis 
on myeloid cells from perfused livers. C) Depletion of Treg cells in FoxP3- DTR 
mice 13 days after administration of Diphtheria toxin (10µg/kg body weight) FACS 
plots are representative of one mouse bled at day 13, prior to sacrifice. D) 
Quantification of CD8 T cell (left) or Treg (right) infiltrates within perfused livers of 
α4-1BB treated mice was measured by flow cytometry. Infiltrates were calculated 
as the total number of cells per liver mass. Bars represent mean ± SD. Statistical 
significance was calculated using a two-sided Student’s T test applying Welch’s 
correction for unequal variance. ns, not significant; *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001.  
 
 
 
 
 
 
  
150 
 
 
 
Chapter 4: General Discussion 
 
 
 
 
General Discussion and Future Directions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
151 
 
 
 
Tumor immunotherapy has shown very promising clinical benefit against an 
array of cancers, however, two major challenges remain unresolved in the field.  
First, many patients do not respond to therapy at all or relapse after a period of 
remission, and a number of cancers remain almost entirely refractory to current 
immunotherapies. Second, there are several immune-related adverse effects 
associated with immune-modulating therapeutic antibodies. Research in the field 
of tumor immunotherapy focuses on improving the efficacy of therapies to expand 
clinical benefit across different tumor types while eliminating unwanted side 
effects.  
The first part of this work focuses on understanding the molecular 
mechanisms of acquired resistance to a triple (αCTLA-4, αPD-1 and αPD-L1) 
combination of checkpoint immunotherapy. Multiple efforts are underway in the 
field to understand the biology of tumor immune evasion in the context of 
immunotherapy. Most of these studies are being conducted on human patient 
samples, which though clinically relevant, limits the ability to utilize genetic 
modification to ask specific biological questions or validate preliminary findings. In 
current preclinical models, it is difficult to distinguish between mice who fail to 
respond due to resistance from mice who fail therapy for purely stochastic reasons. 
Moreover, tumors contain a complex mix of both tumor cells and TME (non-tumor 
cells) constituting pro- and anti-tumor immunity.  In current preclinical tumor 
models and clinical studies, it is very hard to study effects of therapeutic agents on 
tumor cells in isolation from their TME. Studying them separately could be very 
useful for understanding and disrupting the synergy between tumor cells and their 
tumor-supportive tumor microenvironment. We developed a novel mouse 
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melanoma model to address these issues. We have evolved a triple checkpoint 
therapy-resistant B16 melanoma through serial in vivo passage. These tumor cells 
adapted to the presence of immunotherapy over multiple passages, thereby 
enriching a specific genetic signature important for evasion of immunotherapeutic 
pressure. This reduced the signal to noise ratio, enabling the separation of 
immunotherapy responders and non-responders easily.  Tumor cells expressed 
td-tomato fluorescent protein which could be used to FACS sort the tumor cells 
from their microenvironment. 
We investigated tumor cells and TME separately and showed the metabolic 
and immunologic interactions between the two. In our future studies, we aim to 
further divide the TME into two components CD45 positive immune cells and CD45 
negative non-hematopoietic cells in order to highlight the differential effects that 
therapy resistant tumors have on these two cell populations. CD45 positive cells 
in the TME can include anti-tumor CD4/CD8 effector T cells and dendritic cells, 
and studying them separately will help us explore the resistance mechanisms in 
different tumor types.  
 Resistant tumors have upregulated glycolysis and oxidative 
phosphorylation to achieve hyper-metabolic states. We believe that hyper-
metabolic tumor cells deplete essential nutrients from the tumor microenvironment, 
thereby starving CD8 T cells. Hence, CD8 T cells lose their metabolic fitness 
(metabolic insufficiency) to perform effector functions. Surprisingly, MDSC and 
Treg are able to thrive in this unfavorable tumor microenvironment and become 
more immune-suppressive. It would be interesting to delineate the mechanisms 
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underlying the ability of MDSCs and Tregs to survive and function in this nutrient-
depleted TME. 
 We imaged the metabolic profile of resistant tumors using a hyperpolarized 
pyruvate and non-invasive MRI technique, and separated resistant tumors from 
parental based on their metabolic signatures. The hyperpolarized pyruvate and 
MRI imaging technique is already in clinical trials for other indications and could 
be potentially applied in an immuno-oncology setting to predict responses to 
immunotherapy. These findings need to be further validated in a slow-growing 
tumor model, which is partially sensitive to immunotherapy. In slow growing tumor 
models, a metabolic signature could be imaged before and during therapy to 
predict the likelihood of response. This will help us confirm if the imaging technique 
can be used to predict responsiveness in clinic.  
The second part of this work focuses on characterizing mechanisms of 
immune-related hepatotoxicity associated with 4-1BB agonist antibodies. Despite 
the unprecedented success of 4-1BB (CD137) agonist antibodies in preclinical 
studies as mono- and combination therapies, clinical development of 4-1BB 
agonist antibodies has been hampered by dose-limiting liver toxicity.  We describe 
a pathway by which 4-1BB activation on liver myeloid cells initiates inflammatory 
cytokine production, particularly interleukin-27, and progressed towards activation 
of hepatotoxic CD8 T cells. 
Bone marrow-derived monocytes, involved in routine immune surveillance 
in liver tissue, express 4-1BB on their surface at a basal level. In response to 4-
1BB co-stimulation, they release inflammatory cytokines which further upregulate 
4-1BB expression on resident Kupffer cells.  In response to 4-1BB mediated 
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activation, bone marrow derived monocytes and resident Kupffer cells release 
interleukin-27 (IL-27), which initiates a cascade of inflammatory cytokine 
production.  In the clinic, IRAE associated with immunomodulatory antibodies are 
readily managed with steroid intervention. While checkpoint blockade antibody-
induced IRAE mediated by T cells can be managed with steroid interventions, 4-
1BB agonist antibody-induced liver inflammation initiated by myeloid cells is 
difficult to control with steroids. We also demonstrated that IL-27 is a critical 
regulator of α4-1BB induced liver toxicity.  Remarkably, genetic abrogation of IL-
27 (EBI3-/- ) or its receptor (IL27Rα-/-) completely abolished the capacity for 4-1BB 
agonists to mediate hepatic pathology as demonstrated by reduced levels of serum 
AST and ALT, as well as significant reductions in T cell infiltrates in the liver. Even 
though IL-27 could be a potential therapeutic target to explore for controlling 4-
1BB induced liver inflammation, it needs to be further characterized.  Its immune-
regulatory role in individual tumor types has to be elucidated since IL-27 has both 
pro- and anti-inflammatory functions (242).  
We have confirmed the findings from earlier studies that CTLA-4 blockade 
reduces 4-1BB induced liver pathology (94,209). In our previous preclinical studies 
we have shown that combining 4-1BB agonist antibodies with CTLA-4 blockade 
antibodies provides synergistic survival benefit in the B16 melanoma model. Given 
that this combination also shows therapeutic synergy and the capacity to limit IRAE 
associated with αCTLA-4 treatment (94,209), it would be interesting to investigate 
its efficacy in the clinic. In future studies, we will delineate the cellular and 
molecular pathways of αCTLA-4 mediated reduction in liver pathology, which could 
serve as potential therapeutic targets.  
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About 75% of the blood supply in the liver comes from the portal vein 
(venous blood from the intestine) and is continuously exposed to food and 
microbial antigens from the intestine (243-245). Processing of food by the liver 
could produce substantial foreign antigen exposure (245,246). To prevent immune 
system over-activation, the liver maintains a local immune tolerant 
microenvironment and serves as a barrier to environmental antigens (245,246). 
The local and systemic tolerance to self and foreign antigens in the liver is 
maintained by non-parenchymal liver cells such dendritic cells (DCs), Kupffer cells 
(KCs), Treg, and hepatic stellate cells (HSCs) (245,246). We believe that 4-1BB 
agonist antibodies break this immune tolerance by activating Kupffer cells. 
Potentially, this could be due to the ability of 4-1BB co-stimulation to enhance 
antigen presentation, suggested by increased in MHC-II expression on Kupffer 
cells and presentation of foreign antigens to T cells. We have demonstrated that 
4-1BB antibody treatment increases infiltration of CD8 T cells into the liver, where 
they act as primary effectors of hepatic damage. Using β2M-/- mice we have shown 
that both CD8 T cells and MHC-I antigen presentation in the liver are required for 
4-1BB induced hepatotoxicity. This also suggests that the key to potent anti-tumor 
effects related to 4-1BB agonist antibodies lies in the ability of strong 4-1BB co-
stimulation to break self-tolerance. We showed that Foxp3+ regulatory T cells, 
which also play a key role in maintaining liver immune tolerance (247), tried to 
suppress α4-1BB induced liver inflammation as a compensatory mechanism, and 
αCTLA-4 mediated amelioration of liver inflammation is due increase of Treg cells 
in liver parenchyma. Further work needs to be done to delineate the mechanism 
of αCTLA-4 driven increased in Treg infiltration into the liver parenchyma.  
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To divert therapy-induced immune responses towards tumors without 
causing hepatic immune inflammation, we used a chemokine modulation 
approach. Using knockout mice lacking individual chemokine receptors, we went 
on to show that T cell chemotaxis into the liver could be uncoupled from T cell 
trafficking into the tumor, thus maintaining anti-tumor responses generated by α4-
1BB while limiting infiltration of hepatotoxic T cells into the liver. Particularly, the 
chemokine receptors CCR2 and CXCR3 appear to be important for T cell and/or 
monocyte trafficking into the liver and subsequent promotion of hepatic damage, 
without impacting anti-tumor responses.  The impact of CCR2 knockout in 
abrogating liver toxicity remains enticing, as small molecule inhibitors targeting 
CCR2 are currently being considered as immunotherapeutic agents to inhibit the 
recruitment of monocytes into the tumor microenvironment. CCR2 inhibitors when 
combined with 4-1BB agonist antibodies may prove to be a potent combination in 
promoting tumor regression while inhibiting off-target liver toxicity.  
In conclusion, our data demonstrate that tumors can upregulate glycolysis, 
oxidoreductase, and mitochondrial mediated oxidative phosphorylation to evade 
the response to anti-CTLA-4, anti-PD-1 and anti-PD-L1 immunotherapies. 4-1BB 
agonist antibodies trigger hepatitis via activation and expansion of interleukin-27-
producing liver Kupffer cells and monocytes.  Co-administration of CTLA-4 and/or 
CCR2 blockade may minimize hepatitis, while yielding equal or greater antitumor 
immunity.  
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